Acronyms of Clinical Trial Names: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 21: | Line 21: | ||
| [[Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel]] | | [[Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel]] | ||
|- | |- | ||
| 4D | | [[4D]] | ||
| [[Deutsche Diabetes Dialysis Study]] | | [[Deutsche Diabetes Dialysis Study]] | ||
|- | |- | ||
| 4E | | [[4E]] | ||
| [[Efficacy And Safety Of Eplerenone, Enalapril, And Eplerenone/Enalapril Combination Therapy In Patients With Left Ventricular Hypertrophy]] | | [[Efficacy And Safety Of Eplerenone, Enalapril, And Eplerenone/Enalapril Combination Therapy In Patients With Left Ventricular Hypertrophy]] | ||
|- | |- | ||
| 4S | | [[4S]] | ||
| [[Scandinavian Simvastatin Survival Study]] | | [[Scandinavian Simvastatin Survival Study]] | ||
|- | |- | ||
| 6C trial | | [[6C trial]] | ||
| [[Cooperative Colorectal Cancer Combination Chemotherapy Clinical]] | | [[Cooperative Colorectal Cancer Combination Chemotherapy Clinical]] | ||
|- | |- | ||
| A to Z, Phase A | | [[A to Z, Phase A]] | ||
| [[Aggrastat To Zocor]] | | [[Aggrastat To Zocor]] | ||
|- | |- | ||
| A to Z, Phase Z | | [[A to Z, Phase Z]] | ||
| [[Evaluation Of Early Versus Delayed Initiation Of Simvastatin In Patients Who Receive Guideline Based Treatment For Acute Coronary Syndrome]] | | [[Evaluation Of Early Versus Delayed Initiation Of Simvastatin In Patients Who Receive Guideline Based Treatment For Acute Coronary Syndrome]] | ||
|- | |- | ||
| A4 Study | | [[A4 Study]] | ||
| [[Catheter Ablation Versus Antiarrhythmic Drugs For Atrial Fibrillation]] | | [[Catheter Ablation Versus Antiarrhythmic Drugs For Atrial Fibrillation]] | ||
|- | |- | ||
| AAASPS | | [[AAASPS]] | ||
| [[African American Antiplatelet Stroke Prevention Study]] | | [[African American Antiplatelet Stroke Prevention Study]] | ||
|- | |- | ||
| AACHEN | | [[AACHEN]] | ||
| [[Angiotensin II Receptor Blocker Candesartan Cilexetil On Intimal Hyperplasia After Coronary Stent Implantation]] | | [[Angiotensin II Receptor Blocker Candesartan Cilexetil On Intimal Hyperplasia After Coronary Stent Implantation]] | ||
|- | |- | ||
| AASK | | [[AASK]] | ||
| [[African American Study Of Kidney Disease And Hypertension]] | | [[African American Study Of Kidney Disease And Hypertension]] | ||
|- | |- | ||
| ABACAS | | [[ABACAS]] | ||
| [[Adjunctive Balloon Angioplasty Following Coronary Atherectomy Study]] | | [[Adjunctive Balloon Angioplasty Following Coronary Atherectomy Study]] | ||
|- | |- | ||
| ABC study | | [[ABC study]] | ||
| [[Association Of Black Cardiologists Study Of Hypertension]] | | [[Association Of Black Cardiologists Study Of Hypertension]] | ||
|- | |- | ||
| ABCD | | [[ABCD]] | ||
| [[Alternans Before Cardioverter Defibrillator]] | | [[Alternans Before Cardioverter Defibrillator]] | ||
|- | |- | ||
| AbESTT | | [[AbESTT]] | ||
| [[Abciximab Emergent Stroke Treatment Trial]] | | [[Abciximab Emergent Stroke Treatment Trial]] | ||
|- | |- | ||
| ABOARD | | [[ABOARD]] | ||
| [[Immediate Versus Next Day Catheterization In Non-St Elevation Acute Coronary Syndrome]] | | [[Immediate Versus Next Day Catheterization In Non-St Elevation Acute Coronary Syndrome]] | ||
|- | |- | ||
| ABSORB: 6-month and 2-year results | | [[ABSORB: 6-month and 2-year results]] | ||
| [[A Bioabsorbable Everolimus-Eluting Coronary Stent System For Patients With Single De-Novo Coronary Artery Lesions]] | | [[A Bioabsorbable Everolimus-Eluting Coronary Stent System For Patients With Single De-Novo Coronary Artery Lesions]] | ||
|- | |- | ||
| ACADEMIC | | [[ACADEMIC]] | ||
| [[Azithromycin In Coronary Artery Disease: Elimination Of Myocardial Infection With Chlamydia]] | | [[Azithromycin In Coronary Artery Disease: Elimination Of Myocardial Infection With Chlamydia]] | ||
|- | |- | ||
| ACAS | | [[ACAS]] | ||
| [[Asymptomatic Carotid Atherosclerosis Study]] | | [[Asymptomatic Carotid Atherosclerosis Study]] | ||
|- | |- | ||
| ACC AMI GAP | | [[ACC AMI GAP]] | ||
| [[American College Of Cardiology Acute Myocardial Infarction Guidelines Applied To Practice Study]] | | [[American College Of Cardiology Acute Myocardial Infarction Guidelines Applied To Practice Study]] | ||
|- | |- | ||
| ACCENT | | [[ACCENT]] | ||
| [[A Crohn's Disease Clinical Trial Evaluating Infliximab In A New Long-Term Treatment Regimen]] | | [[A Crohn's Disease Clinical Trial Evaluating Infliximab In A New Long-Term Treatment Regimen]] | ||
|- | |- | ||
| ACCEPT | | [[ACCEPT]] | ||
| [[The Accupril Canadian Clinical Evaluation And Patient Teaching Study]] | | [[The Accupril Canadian Clinical Evaluation And Patient Teaching Study]] | ||
|- | |- | ||
| ACCESS | | [[ACCESS]] | ||
| [[Acute Candesartan Cilexetil Evaluation In Stroke Survivors]] | | [[Acute Candesartan Cilexetil Evaluation In Stroke Survivors]] | ||
|- | |- | ||
| ACCLAIM | | [[ACCLAIM]] | ||
| [[Advanced Chronic Heart Failure Clinical Assessment Of Immune Modulation Therapy]] | | [[Advanced Chronic Heart Failure Clinical Assessment Of Immune Modulation Therapy]] | ||
|- | |- | ||
| ACCOMPLISH | | [[ACCOMPLISH]] | ||
| [[Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension]] | | [[Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension]] | ||
|- | |- | ||
| ACCORD | | [[ACCORD]] | ||
| [[Action To Control Cardiovascular Risk In Diabetes]] | | [[Action To Control Cardiovascular Risk In Diabetes]] | ||
|- | |- | ||
| ACCT | | [[ACCT]] | ||
| [[Sex And Age Related Antihypertensive Effects Of Amlodipine]] | | [[Sex And Age Related Antihypertensive Effects Of Amlodipine]] | ||
|- | |- | ||
| ACCURACY | | [[ACCURACY]] | ||
| [[Assessment By Coronary Computed Tomographic Angiography Of Individuals Undergoing Invasive Coronary Angiography]] | | [[Assessment By Coronary Computed Tomographic Angiography Of Individuals Undergoing Invasive Coronary Angiography]] | ||
|- | |- | ||
| ACE | | [[ACE]] | ||
| [[Abciximab-Carbostent Evaluation]] | | [[Abciximab-Carbostent Evaluation]] | ||
|- | |- | ||
| ACE | | [[ACE]] | ||
| [[Anticoagulation For Cardioversion Using Enoxaparin]] | | [[Anticoagulation For Cardioversion Using Enoxaparin]] | ||
|- | |- | ||
| ACE (Carotid Endarterectomy) | | [[ACE (Carotid Endarterectomy)]] | ||
| [[Asa And Carotid Endarterectomy Trial]] | | [[Asa And Carotid Endarterectomy Trial]] | ||
|- | |- | ||
| ACES | | [[ACES]] | ||
| [[Azithromycin And Coronary Events Study In Patients With Stable Coronary Disease]] | | [[Azithromycin And Coronary Events Study In Patients With Stable Coronary Disease]] | ||
|- | |- | ||
| ACES | | [[ACES]] | ||
| [[Clinical Experience Study]] | | [[Clinical Experience Study]] | ||
|- | |- | ||
| ACIP | | [[ACIP]] | ||
| [[Asymptomatic Cardiac Ischemia Pilot Study]] | | [[Asymptomatic Cardiac Ischemia Pilot Study]] | ||
|- | |- | ||
| ACME | | [[ACME]] | ||
| [[Angioplasty Compared To Medicine]] | | [[Angioplasty Compared To Medicine]] | ||
|- | |- | ||
| ACME-2 | | [[ACME-2]] | ||
| [[Angioplasty Compared To Medicine - Two-Vessel Disease]] | | [[Angioplasty Compared To Medicine - Two-Vessel Disease]] | ||
|- | |- | ||
| A-COMET-I | | [[A-COMET-I]] | ||
| [[Azimilide—Cardioversion Maintenance Trial–I]] | | [[Azimilide—Cardioversion Maintenance Trial–I]] | ||
|- | |- | ||
| A-COMET-II | | [[A-COMET-II]] | ||
| [[Azimilide—Cardioversion Maintenance Trial–II]] | | [[Azimilide—Cardioversion Maintenance Trial–II]] | ||
|- | |- | ||
| ACORN | | [[ACORN]] | ||
| [[Assessment Of A Cardiac Support Device (Csd) In Patients With Heart Failure]] | | [[Assessment Of A Cardiac Support Device (Csd) In Patients With Heart Failure]] | ||
|- | |- | ||
| ACRE | | [[ACRE]] | ||
| [[Appropriateness Of Coronary Revascularization]] | | [[Appropriateness Of Coronary Revascularization]] | ||
|- | |- | ||
| ACST | | [[ACST]] | ||
| [[Asymptomatic Carotid Surgery Trial]] | | [[Asymptomatic Carotid Surgery Trial]] | ||
|- | |- | ||
| ACT | | [[ACT]] | ||
| [[Effects Of Physical Activity Counseling In Primary Care: The Activity Counseling Trial]] | | [[Effects Of Physical Activity Counseling In Primary Care: The Activity Counseling Trial]] | ||
|- | |- | ||
| ACT | | [[ACT]] | ||
| [[Angioplasty Compliance Trial]] | | [[Angioplasty Compliance Trial]] | ||
|- | |- | ||
| ACTION | | [[ACTION]] | ||
| [[Coronary Disease Trial Investigating Outcome With Nifedipine Gits]] | | [[Coronary Disease Trial Investigating Outcome With Nifedipine Gits]] | ||
|- | |- | ||
| ACTION | | [[ACTION]] | ||
| [[Actinomycin Eluting Stent Improves Outcomes By Reducing Neointimal Hyperplasia]] | | [[Actinomycin Eluting Stent Improves Outcomes By Reducing Neointimal Hyperplasia]] | ||
|- | |- | ||
| ACTIV in CHF | | [[ACTIV in CHF]] | ||
| [[Acute And Chronic Therapeutic Impact Of A Vasopressin 2 Antagonist (Tolvaptan) In Congestive Heart Failure]] | | [[Acute And Chronic Therapeutic Impact Of A Vasopressin 2 Antagonist (Tolvaptan) In Congestive Heart Failure]] | ||
|- | |- | ||
| ACTIVATE | | [[ACTIVATE]] | ||
| [[Acat Inhibition On The Progression Of Coronary Atherosclerosis]] | | [[Acat Inhibition On The Progression Of Coronary Atherosclerosis]] | ||
|- | |- | ||
| ACTIVE A | | [[ACTIVE A]] | ||
| [[The Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events]] | | [[The Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events]] | ||
|- | |- | ||
| ACTIVE W | | [[ACTIVE W]] | ||
| [[Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events]] | | [[Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events]] | ||
|- | |- | ||
| ACUITY | | [[ACUITY]] | ||
| [[Acute Catheterization And Urgent Intervention Triage Strategy Trial]] | | [[Acute Catheterization And Urgent Intervention Triage Strategy Trial]] | ||
|- | |- | ||
| ACUITY PCI: 30-day and 1-Year Results | | [[ACUITY PCI: 30-day and 1-Year Results]] | ||
| [[Acute Catheterization And Urgent Intervention Triage Strategy Trial - Pci Subgroup: 30-Day And 1-Year Results]] | | [[Acute Catheterization And Urgent Intervention Triage Strategy Trial - Pci Subgroup: 30-Day And 1-Year Results]] | ||
|- | |- | ||
| ACUITY Timing Trial | | [[ACUITY Timing Trial]] | ||
| [[Acute Catheterization And Urgent Intervention Triage Strategy Timing Trial]] | | [[Acute Catheterization And Urgent Intervention Triage Strategy Timing Trial]] | ||
|- | |- | ||
| ACUTE | | [[ACUTE]] | ||
| [[Assessment Of Cardioversion Using Transesophageal Echocardiography]] | | [[Assessment Of Cardioversion Using Transesophageal Echocardiography]] | ||
|- | |- | ||
| ACUTE | | [[ACUTE]] | ||
| [[Analysis Of Coronary Ultrasound Thrombolysis Endpoints In Acute Myocardial Infarction]] | | [[Analysis Of Coronary Ultrasound Thrombolysis Endpoints In Acute Myocardial Infarction]] | ||
|- | |- | ||
| ACUTE II | | [[ACUTE II]] | ||
| [[Assessment Of Cardioversion Using Transesophageal Echocardiography]] | | [[Assessment Of Cardioversion Using Transesophageal Echocardiography]] | ||
|- | |- | ||
| ADAM | | [[ADAM]] | ||
| [[Aneurysm Detection And Management Veterans Affairs Cooperative Study]] | | [[Aneurysm Detection And Management Veterans Affairs Cooperative Study]] | ||
|- | |- | ||
| ADAM | | [[ADAM]] | ||
| [[Amsterdam Duration Of Antiretroviral Medication Study]] | | [[Amsterdam Duration Of Antiretroviral Medication Study]] | ||
|- | |- | ||
| ADAPT | | [[ADAPT]] | ||
| [[Alzheimer's Disease Anti-Inflammatory Prevention Trial]] | | [[Alzheimer's Disease Anti-Inflammatory Prevention Trial]] | ||
|- | |- | ||
| ADCS | | [[ADCS]] | ||
| [[Alzheimer's Disease Cooperative Study]] | | [[Alzheimer's Disease Cooperative Study]] | ||
|- | |- | ||
| ADEMEX | | [[ADEMEX]] | ||
| [[Adequacy Of Peritoneal Dialysis In Mexico]] | | [[Adequacy Of Peritoneal Dialysis In Mexico]] | ||
|- | |- | ||
| ADEPT | | [[ADEPT]] | ||
| [[Advanced Elements Of Pacing Trial]] | | [[Advanced Elements Of Pacing Trial]] | ||
|- | |- | ||
| ADIOS | | [[ADIOS]] | ||
| [[Antiarrhythmic Drug Improve Outcome Study]] | | [[Antiarrhythmic Drug Improve Outcome Study]] | ||
|- | |- | ||
| ADMIRAL | | [[ADMIRAL]] | ||
| [[Platelet Glycoprotein IIb/IIia Inhibition With Coronary Stenting For Acute Myocardial Infarction]] | | [[Platelet Glycoprotein IIb/IIia Inhibition With Coronary Stenting For Acute Myocardial Infarction]] | ||
|- | |- | ||
| ADMIRAL | | [[ADMIRAL]] | ||
| [[Abciximab Before Direct Angioplasty And Stenting In Myocardial Infarction Regarding Acute And Long-Term Followup]] | | [[Abciximab Before Direct Angioplasty And Stenting In Myocardial Infarction Regarding Acute And Long-Term Followup]] | ||
|- | |- | ||
| ADMIT | | [[ADMIT]] | ||
| [[Arterial Disease Multiple Intervention Trial]] | | [[Arterial Disease Multiple Intervention Trial]] | ||
|- | |- | ||
| ADONIS | | [[ADONIS]] | ||
| [[Aspirin Dose Optimized In Noncardioembolic Ischemic Stroke]] | | [[Aspirin Dose Optimized In Noncardioembolic Ischemic Stroke]] | ||
|- | |- | ||
| ADOPT | | [[ADOPT]] | ||
| [[Atrial Dynamic Overdrive Pacing Trial]] | | [[Atrial Dynamic Overdrive Pacing Trial]] | ||
|- | |- | ||
| ADOPT | | [[ADOPT]] | ||
| [[A Diabetes Outcome Progression Trial]] | | [[A Diabetes Outcome Progression Trial]] | ||
|- | |- | ||
| ADOPT-A | | [[ADOPT-A]] | ||
| [[Atrial Dynamic Overdrive Pacing Trial-A]] | | [[Atrial Dynamic Overdrive Pacing Trial-A]] | ||
|- | |- | ||
| ADVANCE | | [[ADVANCE]] | ||
| [[A Randomized Comparison Of The Value Of Additional Stenting After Optimal Balloon Angioplasty For Long Coronary Lesions]] | | [[A Randomized Comparison Of The Value Of Additional Stenting After Optimal Balloon Angioplasty For Long Coronary Lesions]] | ||
|- | |- | ||
| ADVANCE | | [[ADVANCE]] | ||
| [[Additive Value Of Tirofiban Administered With The High-Dose Bolus In The Prevention Of Ischemic Complications During High-Risk Coronary Angioplasty]] | | [[Additive Value Of Tirofiban Administered With The High-Dose Bolus In The Prevention Of Ischemic Complications During High-Risk Coronary Angioplasty]] | ||
|- | |- | ||
| ADVANCE | | [[ADVANCE]] | ||
| [[Action In Diabetes And Vascular Disease: Preterax And Diamicron Modified Release Controlled Evaluation]] | | [[Action In Diabetes And Vascular Disease: Preterax And Diamicron Modified Release Controlled Evaluation]] | ||
|- | |- | ||
| ADVANCE | | [[ADVANCE]] | ||
| [[A Dosing Evaluation Of A Vasopressin Antagonist In Chf Patients Undergoing Exercise]] | | [[A Dosing Evaluation Of A Vasopressin Antagonist In Chf Patients Undergoing Exercise]] | ||
|- | |- | ||
| ADVENT | | [[ADVENT]] | ||
| [[Assessment Of Diabetes Control And Evaluation Of The Efficacy Of Niaspan Trial]] | | [[Assessment Of Diabetes Control And Evaluation Of The Efficacy Of Niaspan Trial]] | ||
|- | |- | ||
| AEGIS | | [[AEGIS]] | ||
| [[Alternative Graft Investigational Study]] | | [[Alternative Graft Investigational Study]] | ||
|- | |- | ||
| A-F | | [[A-F]] | ||
| [[Vascular Protection In High-Risk Non–St-Elevation Acute Coronary Syndromes: The Angioplasty Balloon-Associated Coronary Debris And The Ez Filterwire]] | | [[Vascular Protection In High-Risk Non–St-Elevation Acute Coronary Syndromes: The Angioplasty Balloon-Associated Coronary Debris And The Ez Filterwire]] | ||
|- | |- | ||
| AFASAK | | [[AFASAK]] | ||
| [[Atrial Fibrillation, Aspirin, Antikoagulation]] | | [[Atrial Fibrillation, Aspirin, Antikoagulation]] | ||
|- | |- | ||
| AFASAK-2 | | [[AFASAK-2]] | ||
| [[Second Copenhagen Atrial Fibrillation, Aspirin, And Anticoagulation Study]] | | [[Second Copenhagen Atrial Fibrillation, Aspirin, And Anticoagulation Study]] | ||
|- | |- | ||
| AFCAPS | | [[AFCAPS]] | ||
| [[Air Force Coronary Atherosclerosis Prevention Study]] | | [[Air Force Coronary Atherosclerosis Prevention Study]] | ||
|- | |- | ||
| AFCAPS/TEXCAPS | | [[AFCAPS/TEXCAPS]] | ||
| [[Air Force Texas Coronary Atherosclerosis Prevention Study]] | | [[Air Force Texas Coronary Atherosclerosis Prevention Study]] | ||
|- | |- | ||
| AF-CHF | | [[AF-CHF]] | ||
| [[Atrial Fibrillation And Congestive Heart Failure]] | | [[Atrial Fibrillation And Congestive Heart Failure]] | ||
|- | |- | ||
| AFFIRM | | [[AFFIRM]] | ||
| [[Atrial Fibrillation Follow-Up Investigation Of Rhythm Management]] | | [[Atrial Fibrillation Follow-Up Investigation Of Rhythm Management]] | ||
|- | |- | ||
| AFIB | | [[AFIB]] | ||
| [[Atrial Fibrillation Investigation With Bidisomide]] | | [[Atrial Fibrillation Investigation With Bidisomide]] | ||
|- | |- | ||
| AFREGS | | [[AFREGS]] | ||
| [[Armed Forces Regression Study]] | | [[Armed Forces Regression Study]] | ||
|- | |- | ||
| AGENT | | [[AGENT]] | ||
| [[Angiogenic Gene Therapy]] | | [[Angiogenic Gene Therapy]] | ||
|- | |- | ||
| AGENT-2 | | [[AGENT-2]] | ||
| [[Angiogenic Gene Therapy Trial]] | | [[Angiogenic Gene Therapy Trial]] | ||
|- | |- | ||
| AGENT-3 | | [[AGENT-3]] | ||
| [[A Multicenter, Prospective, Randomized Trial Of Intracoronary Administration Of Ad5Fgf-4 In Patients With No Revascularization Options]] | | [[A Multicenter, Prospective, Randomized Trial Of Intracoronary Administration Of Ad5Fgf-4 In Patients With No Revascularization Options]] | ||
|- | |- | ||
| AGIS | | [[AGIS]] | ||
| [[Advanced Glaucoma Intervention Study]] | | [[Advanced Glaucoma Intervention Study]] | ||
|- | |- | ||
| A-HeFT | | [[A-HeFT]] | ||
| [[African-American Heart Failure Trial]] | | [[African-American Heart Failure Trial]] | ||
|- | |- | ||
| AiMI | | [[AiMI]] | ||
| [[A Prospective, Randomized, Controlled Trial Of Thrombectomy With The Angiojet In Acute Myocardial Infarction]] | | [[A Prospective, Randomized, Controlled Trial Of Thrombectomy With The Angiojet In Acute Myocardial Infarction]] | ||
|- | |- | ||
| AIMS | | [[AIMS]] | ||
| [[Apsac Intervention Mortality Study]] | | [[Apsac Intervention Mortality Study]] | ||
|- | |- | ||
| AIR | | [[AIR]] | ||
| [[Aerosolized Iloprost Randomized Placebo-Controlled Study]] | | [[Aerosolized Iloprost Randomized Placebo-Controlled Study]] | ||
|- | |- | ||
| Air PAMI | | [[Air PAMI]] | ||
| [[The Air Primary Angioplasty In Myocardial Infarction Study]] | | [[The Air Primary Angioplasty In Myocardial Infarction Study]] | ||
|- | |- | ||
| AIRCRAFT | | [[AIRCRAFT]] | ||
| [[The Australian Intervention Randomized Control Of Rate In Atrial Fibrillation Trial]] | | [[The Australian Intervention Randomized Control Of Rate In Atrial Fibrillation Trial]] | ||
|- | |- | ||
| AIRE | | [[AIRE]] | ||
| [[Acute Infarction Ramipril Efficacy Study]] | | [[Acute Infarction Ramipril Efficacy Study]] | ||
|- | |- | ||
| AIST-ASH | | [[AIST-ASH]] | ||
| [[Acute Ischemic Stroke Trial: Oral Aspirin Vs Intravenous Heparin On Stroke Progression]] | | [[Acute Ischemic Stroke Trial: Oral Aspirin Vs Intravenous Heparin On Stroke Progression]] | ||
|- | |- | ||
| ALBION | | [[ALBION]] | ||
| [[Assessment Of The Best Loading Dose Of Clopidogrel To Blunt Platelet Activation, Inflammation, And On-Going Necrosis]] | | [[Assessment Of The Best Loading Dose Of Clopidogrel To Blunt Platelet Activation, Inflammation, And On-Going Necrosis]] | ||
|- | |- | ||
| ALERT | | [[ALERT]] | ||
| [[Assessment Of Lescol In Renal Transplantation]] | | [[Assessment Of Lescol In Renal Transplantation]] | ||
|- | |- | ||
| ALERT | | [[ALERT]] | ||
| [[Adjunctive Lamictal In Epilepsy And Response To Treatment]] | | [[Adjunctive Lamictal In Epilepsy And Response To Treatment]] | ||
|- | |- | ||
| ALIVE | | [[ALIVE]] | ||
| [[Azimilide Post-Infarct Survival Evaluation]] | | [[Azimilide Post-Infarct Survival Evaluation]] | ||
|- | |- | ||
| ALIVE | | [[ALIVE]] | ||
| [[Adenosine Lidocaine Infarct Zone Viability Enhancement]] | | [[Adenosine Lidocaine Infarct Zone Viability Enhancement]] | ||
|- | |- | ||
| ALIVE (amio vs. lidocaine | | [[ALIVE (amio vs. lidocaine]] | ||
| [[Amiodarone As Compared With Lidocaine For Shock-Resistant Ventricular Fibrillation]] | | [[Amiodarone As Compared With Lidocaine For Shock-Resistant Ventricular Fibrillation]] | ||
|- | |- | ||
| ALKK | | [[ALKK]] | ||
| [[Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte]] | | [[Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte]] | ||
|- | |- | ||
| ALLAY | | [[ALLAY]] | ||
| [[Aliskiren In Left Ventricular Hypertrophy]] | | [[Aliskiren In Left Ventricular Hypertrophy]] | ||
|- | |- | ||
| ALLHAT | | [[ALLHAT]] | ||
| [[Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial]] | | [[Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial]] | ||
|- | |- | ||
| ALLHAT Lipid Lowering Trial | | [[ALLHAT Lipid Lowering Trial]] | ||
| [[Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial]] | | [[Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial]] | ||
|- | |- | ||
| ALLIANCE | | [[ALLIANCE]] | ||
| [[Aggressive Lipid-Lowering Initiation Abates New Cardiac Events]] | | [[Aggressive Lipid-Lowering Initiation Abates New Cardiac Events]] | ||
|- | |- | ||
| ALOFT | | [[ALOFT]] | ||
| [[Aliskiren Observations Of Heart Failure Treatment]] | | [[Aliskiren Observations Of Heart Failure Treatment]] | ||
|- | |- | ||
| ALPHA | | [[ALPHA]] | ||
| [[T-Wave Alternans In Patients With Heart Failure]] | | [[T-Wave Alternans In Patients With Heart Failure]] | ||
|- | |- | ||
| ALPHABET | | [[ALPHABET]] | ||
| [[Effects Of Beraprost Sodium, An Oral Prostacyclin Analogue, In Patients With Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial]] | | [[Effects Of Beraprost Sodium, An Oral Prostacyclin Analogue, In Patients With Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial]] | ||
|- | |- | ||
| ALTS | | [[ALTS]] | ||
| [[Ascus/Lsil Triage Study ]] | | [[Ascus/Lsil Triage Study ]] | ||
|- | |- | ||
| AMADEUS | | [[AMADEUS]] | ||
| [[Comparison Of Idraparinux With Vitamin K Antagonists For Prevention Of Thromboembolism In Patients With Atrial Fibrillation]] | | [[Comparison Of Idraparinux With Vitamin K Antagonists For Prevention Of Thromboembolism In Patients With Atrial Fibrillation]] | ||
|- | |- | ||
| AMAZE | | [[AMAZE]] | ||
| [[A Multicenter Trial Using-Zestril Versus To Evaluate The Effects On Lowering Blood Pressure ]] | | [[A Multicenter Trial Using-Zestril Versus To Evaluate The Effects On Lowering Blood Pressure ]] | ||
|- | |- | ||
| AMEthyst | | [[AMEthyst]] | ||
| [[Assessment Of The Medtronic Ave Interceptor Saphenous Vein Graft Filter System]] | | [[Assessment Of The Medtronic Ave Interceptor Saphenous Vein Graft Filter System]] | ||
|- | |- | ||
| AMIGO | | [[AMIGO]] | ||
| [[Atherectomy And Multilink Stenting Improves Gain In Outcome Trial]] | | [[Atherectomy And Multilink Stenting Improves Gain In Outcome Trial]] | ||
|- | |- | ||
| AMIGO | | [[AMIGO]] | ||
| [[Ac2993: Diabetes Management For Improving Glucose Outcome]] | | [[Ac2993: Diabetes Management For Improving Glucose Outcome]] | ||
|- | |- | ||
| AMIHOT | | [[AMIHOT]] | ||
| [[Acute Myocardial Infarction With Hyperoxemic Therapy]] | | [[Acute Myocardial Infarction With Hyperoxemic Therapy]] | ||
|- | |- | ||
| AMIHOT II | | [[AMIHOT II]] | ||
| [[Acute Myocardial Infarction With Hyperoxemic Therapy II]] | | [[Acute Myocardial Infarction With Hyperoxemic Therapy II]] | ||
|- | |- | ||
| AMIOVIRT | | [[AMIOVIRT]] | ||
| [[Amiodarone Versus Implantable Defibrillator In Patients With Nonischemic Cardiomyopathy And Asymptomatic Nonsustained Ventricular Tachycardia Study]] | | [[Amiodarone Versus Implantable Defibrillator In Patients With Nonischemic Cardiomyopathy And Asymptomatic Nonsustained Ventricular Tachycardia Study]] | ||
|- | |- | ||
| AMISTAD | | [[AMISTAD]] | ||
| [[Acute Myocardial Infarction Study Of Adenosine]] | | [[Acute Myocardial Infarction Study Of Adenosine]] | ||
|- | |- | ||
| AMISTAD I | | [[AMISTAD I]] | ||
| [[Acute Myocardial Infarction Study Of Adenosine Trial]] | | [[Acute Myocardial Infarction Study Of Adenosine Trial]] | ||
|- | |- | ||
| AMISTAD II | | [[AMISTAD II]] | ||
| [[Acute Myocardial Infarction Study Of Adenosine II]] | | [[Acute Myocardial Infarction Study Of Adenosine II]] | ||
|- | |- | ||
| AMRO | | [[AMRO]] | ||
| [[Amsterdam-Rotterdam Trial]] | | [[Amsterdam-Rotterdam Trial]] | ||
|- | |- | ||
| ANBP2 | | [[ANBP2]] | ||
| [[Australian National Blood Pressure Study Group]] | | [[Australian National Blood Pressure Study Group]] | ||
|- | |- | ||
| ANDROMEDA | | [[ANDROMEDA]] | ||
| [[Increased Mortality After Dronedarone Therapy For Severe Heart Failure]] | | [[Increased Mortality After Dronedarone Therapy For Severe Heart Failure]] | ||
|- | |- | ||
| ANTHEM–TIMI-32 | | [[ANTHEM–TIMI-32]] | ||
| [[Anticoagulation With Rnapc2 To Eliminate Mace/Timi 32]] | | [[Anticoagulation With Rnapc2 To Eliminate Mace/Timi 32]] | ||
|- | |- | ||
| ANTIBIO | | [[ANTIBIO]] | ||
| [[Antibiotic Therapy After An Acute Myocardial Infarction]] | | [[Antibiotic Therapy After An Acute Myocardial Infarction]] | ||
|- | |- | ||
| ANZ-Carvedilol | | [[ANZ-Carvedilol]] | ||
| [[Australia-New Zealand Heart Failure Research Collaborative Group Carvedilol Trial]] | | [[Australia-New Zealand Heart Failure Research Collaborative Group Carvedilol Trial]] | ||
|- | |- | ||
| APAF | | [[APAF]] | ||
| [[Ablation For Paroxysmal Atrial Fibrillation (Apaf) Trial]] | | [[Ablation For Paroxysmal Atrial Fibrillation (Apaf) Trial]] | ||
|- | |- | ||
| APASS | | [[APASS]] | ||
| [[Antiphospholipid Antibody Stroke Study]] | | [[Antiphospholipid Antibody Stroke Study]] | ||
|- | |- | ||
| APC | | [[APC]] | ||
| [[Adenoma Prevention With Celecoxib]] | | [[Adenoma Prevention With Celecoxib]] | ||
|- | |- | ||
| APEX AMI | | [[APEX AMI]] | ||
| [[Assessment Of Pexelizumab In Acute Myocardial Infarction]] | | [[Assessment Of Pexelizumab In Acute Myocardial Infarction]] | ||
|- | |- | ||
| APLAUSE | | [[APLAUSE]] | ||
| [[Anti-Platelet Treatment After Intravascular Ultrasound Guided Optimal Stent Expansion]] | | [[Anti-Platelet Treatment After Intravascular Ultrasound Guided Optimal Stent Expansion]] | ||
|- | |- | ||
| APOCARD | | [[APOCARD]] | ||
| [[Imaging In Cardiac Transplant Patients]] | | [[Imaging In Cardiac Transplant Patients]] | ||
|- | |- | ||
| APPRAISE-1 | | [[APPRAISE-1]] | ||
| [[Safety Of The Factor Xa Inhibitor, Apixaban, In Combination With Antiplatelet Therapy After Acute Coronary Syndromes: A Dose-Guiding Trial]] | | [[Safety Of The Factor Xa Inhibitor, Apixaban, In Combination With Antiplatelet Therapy After Acute Coronary Syndromes: A Dose-Guiding Trial]] | ||
|- | |- | ||
| APPROACH | | [[APPROACH]] | ||
| [[Assessment On The Prevention Of Progression By Rosiglitazone On Atherosclerosis In Diabetes Patients With Cardiovascular History]] | | [[Assessment On The Prevention Of Progression By Rosiglitazone On Atherosclerosis In Diabetes Patients With Cardiovascular History]] | ||
|- | |- | ||
| APRES | | [[APRES]] | ||
| [[Angiotensin-Converting Enzyme Inhibition Post Revascularization Study]] | | [[Angiotensin-Converting Enzyme Inhibition Post Revascularization Study]] | ||
|- | |- | ||
| APRICOT | | [[APRICOT]] | ||
| [[Antithrombotics In The Prevention Of Reocclusion In Coronary Thrombolysis]] | | [[Antithrombotics In The Prevention Of Reocclusion In Coronary Thrombolysis]] | ||
|- | |- | ||
| APRICOT-2 | | [[APRICOT-2]] | ||
| [[Antithrombotics In The Prevention Of Reocclusion In Coronary Thrombolysis-2]] | | [[Antithrombotics In The Prevention Of Reocclusion In Coronary Thrombolysis-2]] | ||
|- | |- | ||
| ARBITER 2 | | [[ARBITER 2]] | ||
| [[Arterial Biology For The Investigation Of The Treatment Effects Of Reducing Cholesterol 2]] | | [[Arterial Biology For The Investigation Of The Treatment Effects Of Reducing Cholesterol 2]] | ||
|- | |- | ||
| ARCH | | [[ARCH]] | ||
| [[Amiodarone Reduction In Coronary Heart Trial]] | | [[Amiodarone Reduction In Coronary Heart Trial]] | ||
|- | |- | ||
| ARCHeR | | [[ARCHeR]] | ||
| [[For Revascularization Of Carotids In High-Risk Patients]] | | [[For Revascularization Of Carotids In High-Risk Patients]] | ||
|- | |- | ||
| AREDS | | [[AREDS]] | ||
| [[Age-Related Eye Disease Study]] | | [[Age-Related Eye Disease Study]] | ||
|- | |- | ||
| ARG-911 | | [[ARG-911]] | ||
| [[Argatroban-911]] | | [[Argatroban-911]] | ||
|- | |- | ||
| ARG-915 | | [[ARG-915]] | ||
| [[Argatroban-915]] | | [[Argatroban-915]] | ||
|- | |- | ||
| ARGAMI-2 | | [[ARGAMI-2]] | ||
| [[Argatroban For Acute Myocardial Infarction]] | | [[Argatroban For Acute Myocardial Infarction]] | ||
|- | |- | ||
| ARIC | | [[ARIC]] | ||
| [[Atherosclerosis Risk In Communities]] | | [[Atherosclerosis Risk In Communities]] | ||
|- | |- | ||
| ARIES 1 and 2 | | [[ARIES 1 and 2]] | ||
| [[Ambrisentan In Pulmonary Arterial Hypertension Efficacy Study 1 And 2]] | | [[Ambrisentan In Pulmonary Arterial Hypertension Efficacy Study 1 And 2]] | ||
|- | |- | ||
| ARISE | | [[ARISE]] | ||
| [[Aggressive Reduction Of Inflammation Stops Events]] | | [[Aggressive Reduction Of Inflammation Stops Events]] | ||
|- | |- | ||
| ARMS | | [[ARMS]] | ||
| [[Apsac Reocclusion Multicenter Study]] | | [[Apsac Reocclusion Multicenter Study]] | ||
|- | |- | ||
| ARMYDA | | [[ARMYDA]] | ||
| [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty]] | | [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty]] | ||
|- | |- | ||
| ARMYDA-2 | | [[ARMYDA-2]] | ||
| [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty Study]] | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty Study]] | ||
|- | |- | ||
| ARMYDA-3 | | [[ARMYDA-3]] | ||
| [[Atorvastatin For Reduction Of Myocardial Dysrhythmias After Cardiac Surgery]] | | [[Atorvastatin For Reduction Of Myocardial Dysrhythmias After Cardiac Surgery]] | ||
|- | |- | ||
| ARMYDA-4 | | [[ARMYDA-4]] | ||
| [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 4]] | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 4]] | ||
|- | |- | ||
| ARMYDA-5 | | [[ARMYDA-5]] | ||
| [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 5]] | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 5]] | ||
|- | |- | ||
| ARMYDA-ACS | | [[ARMYDA-ACS]] | ||
| [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty-Acute Coronary Syndromes]] | | [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty-Acute Coronary Syndromes]] | ||
|- | |- | ||
| ARMYDA-RECAPTURE | | [[ARMYDA-RECAPTURE]] | ||
| [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty]] | | [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty]] | ||
|- | |- | ||
| ARMYDA-RELOAD | | [[ARMYDA-RELOAD]] | ||
| [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty-Reload]] | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty-Reload]] | ||
|- | |- | ||
| ARPEGGIO | | [[ARPEGGIO]] | ||
| [[Rimonabant Improves Glycemic Control In Insulin-Treated Type 2 Diabetes]] | | [[Rimonabant Improves Glycemic Control In Insulin-Treated Type 2 Diabetes]] | ||
|- | |- | ||
| ARREST | | [[ARREST]] | ||
| [[Amiodarone For Resuscitation After Out-Of-Hospital Cardiac Arrest Due To Ventricular Fibrillation]] | | [[Amiodarone For Resuscitation After Out-Of-Hospital Cardiac Arrest Due To Ventricular Fibrillation]] | ||
|- | |- | ||
| ARREST | | [[ARREST]] | ||
| [[Angiorad Radiation For Restenosis]] | | [[Angiorad Radiation For Restenosis]] | ||
|- | |- | ||
| ARTIST | | [[ARTIST]] | ||
| [[Angioplasty Versus Rotational Atherectomy For Treatment Of Diffuse In-Stent Restenosis Trial]] | | [[Angioplasty Versus Rotational Atherectomy For Treatment Of Diffuse In-Stent Restenosis Trial]] | ||
|- | |- | ||
| ARTISTIC | | [[ARTISTIC]] | ||
| [[Angiorad Radiation Therapy For In-Stent Restenosis Intracoronary]] | | [[Angiorad Radiation Therapy For In-Stent Restenosis Intracoronary]] | ||
|- | |- | ||
| ARTS | | [[ARTS]] | ||
| [[Arterial Revascularization Therapies Study]] | | [[Arterial Revascularization Therapies Study]] | ||
|- | |- | ||
| ARTS I - Five year follow-up | | [[ARTS I - Five year follow-up]] | ||
| [[Five Year Clinical Follow-Up Of The Arterial Revascularisation Therapy Study]] | | [[Five Year Clinical Follow-Up Of The Arterial Revascularisation Therapy Study]] | ||
|- | |- | ||
| ARTS-II | | [[ARTS-II]] | ||
| [[Arterial Revascularization Therapies Study Part II: Sirolimus-Eluting Stents For The Treatment Of Patients With Multivessel De Novo Coronary Artery Lesions]] | | [[Arterial Revascularization Therapies Study Part II: Sirolimus-Eluting Stents For The Treatment Of Patients With Multivessel De Novo Coronary Artery Lesions]] | ||
|- | |- | ||
| ASAP | | [[ASAP]] | ||
| [[Effect Of Aggressive Versus Conventional Lipid Lowering On Atherosclerosis Progression In Familial Hypercholesterolemia]] | | [[Effect Of Aggressive Versus Conventional Lipid Lowering On Atherosclerosis Progression In Familial Hypercholesterolemia]] | ||
|- | |- | ||
| ASAP | | [[ASAP]] | ||
| [[Azimilide Supraventricular Arrhythmia Program ]] | | [[Azimilide Supraventricular Arrhythmia Program ]] | ||
|- | |- | ||
| ASCENT | | [[ASCENT]] | ||
| [[Acs Stent Clinical Equivalence In De Novo Lesions Trial]] | | [[Acs Stent Clinical Equivalence In De Novo Lesions Trial]] | ||
|- | |- | ||
| ASCOT | | [[ASCOT]] | ||
| [[Anglo-Scandinavian Cardiac Outcome Trial]] | | [[Anglo-Scandinavian Cardiac Outcome Trial]] | ||
|- | |- | ||
| ASCOT - Blood Pressure Arm | | [[ASCOT - Blood Pressure Arm]] | ||
| [[ Anglo-Scandinavian Cardiac Outcomes Trial: Blood Pressure-Lowering Arm]] | | [[ Anglo-Scandinavian Cardiac Outcomes Trial: Blood Pressure-Lowering Arm]] | ||
|- | |- | ||
| ASCOT - Lipid Arm | | [[ASCOT - Lipid Arm]] | ||
| [[ Anglo-Scandinavian Cardiac Outcomes Trial]] | | [[ Anglo-Scandinavian Cardiac Outcomes Trial]] | ||
|- | |- | ||
| ASFAST | | [[ASFAST]] | ||
| [[Atherosclerosis And Folic Acid Supplementation Trial]] | | [[Atherosclerosis And Folic Acid Supplementation Trial]] | ||
|- | |- | ||
| ASIS | | [[ASIS]] | ||
| [[Angina And Silent Ischemia Study]] | | [[Angina And Silent Ischemia Study]] | ||
|- | |- | ||
| ASPAC | | [[ASPAC]] | ||
| [[Asian-Pacific Collaboration On Chd Risk Factor Intervention]] | | [[Asian-Pacific Collaboration On Chd Risk Factor Intervention]] | ||
|- | |- | ||
| ASPECT | | [[ASPECT]] | ||
| [[Anticoagulants In Secondary Prevention Of Events In Coronary Thrombosis]] | | [[Anticoagulants In Secondary Prevention Of Events In Coronary Thrombosis]] | ||
|- | |- | ||
| ASPECT | | [[ASPECT]] | ||
| [[Asian Paclitaxel-Eluting Stent Clinical Trial]] | | [[Asian Paclitaxel-Eluting Stent Clinical Trial]] | ||
|- | |- | ||
| ASPECT | | [[ASPECT]] | ||
| [[Anticoagulants In The Secondary Prevention Of Events In Coronary Thrombosis ]] | | [[Anticoagulants In The Secondary Prevention Of Events In Coronary Thrombosis ]] | ||
|- | |- | ||
| ASPECT-2 | | [[ASPECT-2]] | ||
| [[Aspirin And Coumadin After Acute Coronary Syndromes (The Aspect-2) Study: A Randomised Controlled Trial.]] | | [[Aspirin And Coumadin After Acute Coronary Syndromes (The Aspect-2) Study: A Randomised Controlled Trial.]] | ||
|- | |- | ||
| ASPEN | | [[ASPEN]] | ||
| [[Atorvastatin Study For The Prevention Of Endpoints For Patients With Niddm]] | | [[Atorvastatin Study For The Prevention Of Endpoints For Patients With Niddm]] | ||
|- | |- | ||
| ASPIRE | | [[ASPIRE]] | ||
| [[Arixtra Study In Percutaneous Coronary Intervention: A Randomized Evaluation]] | | [[Arixtra Study In Percutaneous Coronary Intervention: A Randomized Evaluation]] | ||
|- | |- | ||
| ASSENT | | [[ASSENT]] | ||
| [[Assessment Of The Safety And Efficacy Of A New Thrombolytic]] | | [[Assessment Of The Safety And Efficacy Of A New Thrombolytic]] | ||
|- | |- | ||
| ASSENT 3 | | [[ASSENT 3]] | ||
| [[The Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen (Assent)-3 Investigators. Efficacy And Safety Of Tenecteplase In Combination With Enoxaparin, Abciximab, Or Unfractionated Heparin: The Assent-3 Randomized Trial In Acute Mi]] | | [[The Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen (Assent)-3 Investigators. Efficacy And Safety Of Tenecteplase In Combination With Enoxaparin, Abciximab, Or Unfractionated Heparin: The Assent-3 Randomized Trial In Acute Mi]] | ||
|- | |- | ||
| ASSENT 3 PLUS | | [[[ASSENT 3 PLUS]] | ||
| [[Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen]] | | [[Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen]] | ||
|- | |- | ||
| ASSENT-1 | | [[ASSENT-1]] | ||
| [[Assessment Of The Safety Of A New Thrombolytic: Tnk-Tpa]] | | [[Assessment Of The Safety Of A New Thrombolytic: Tnk-Tpa]] | ||
|- | |- | ||
| ASSENT-2 | | [[ASSENT-2]] | ||
| [[Assessment Of The Safety And Efficacy Of A New Thrombolytic: Tnk-Tpa]] | | [[Assessment Of The Safety And Efficacy Of A New Thrombolytic: Tnk-Tpa]] | ||
|- | |- | ||
| ASSENT-4 PCI | | [[ASSENT-4 PCI]] | ||
| [[Assessment Of The Safety And Efficacy Of A New Treatment Strategy For Acute Myocardial Infarction]] | | [[Assessment Of The Safety And Efficacy Of A New Treatment Strategy For Acute Myocardial Infarction]] | ||
|- | |- | ||
| ASSERT | | [[ASSERT]] | ||
| [[Aortic Stentless Versus Stented Valve Assessed By Echocardiography Randomized Trial]] | | [[Aortic Stentless Versus Stented Valve Assessed By Echocardiography Randomized Trial]] | ||
|- | |- | ||
| ASSET | | [[ASSET]] | ||
| [[Anglo-Scandinavian Study Of Early Thrombolysis]] | | [[Anglo-Scandinavian Study Of Early Thrombolysis]] | ||
|- | |- | ||
| ASSIST | | [[ASSIST]] | ||
| [[Assessment Of Implementation Strategies]] | | [[Assessment Of Implementation Strategies]] | ||
|- | |- | ||
| ASSIST | | [[ASSIST]] | ||
| [[A Stop Smoking In Schools Trial]] | | [[A Stop Smoking In Schools Trial]] | ||
|- | |- | ||
| ASSURE | | [[ASSURE]] | ||
| [[Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit Of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter Defibrillator Implantations]] | | [[Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit Of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter Defibrillator Implantations]] | ||
|- | |- | ||
| ASTAMI | | [[ASTAMI]] | ||
| [[Astami]] | | [[Astami]] | ||
|- | |- | ||
| ASTEROID | | [[ASTEROID]] | ||
| [[A Study To Evaluate The Effect Of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden]] | | [[A Study To Evaluate The Effect Of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden]] | ||
|- | |- | ||
| ASTIS | | [[ASTIS]] | ||
| [[Autologous Stem Cell Transplantation International Scleroderma Trial]] | | [[Autologous Stem Cell Transplantation International Scleroderma Trial]] | ||
|- | |- | ||
| ASTRAL | | [[ASTRAL]] | ||
| [[Angioplasty And Stenting For Renal Artery Lesions]] | | [[Angioplasty And Stenting For Renal Artery Lesions]] | ||
|- | |- | ||
| ASTRID | | [[ASTRID]] | ||
| [[Atrial Sensing Trial To Prevent Inappropriate Detections]] | | [[Atrial Sensing Trial To Prevent Inappropriate Detections]] | ||
|- | |- | ||
| ASTRONAUT | | [[ASTRONAUT]] | ||
| [[Acid Suppression Trial: Ranitidine Zantac Versus Omeprazole]] | | [[Acid Suppression Trial: Ranitidine Zantac Versus Omeprazole]] | ||
|- | |- | ||
| AT LAST | | [[AT LAST]] | ||
| [[Antiretroviral Trial Looking At Sex And Treatment]] | | [[Antiretroviral Trial Looking At Sex And Treatment]] | ||
|- | |- | ||
| ATAC | | [[ATAC]] | ||
| [[Arimidex (Anastrozole), Tamoxifen And Combination Therapy]] | | [[Arimidex (Anastrozole), Tamoxifen And Combination Therapy]] | ||
|- | |- | ||
| ATBAT | | [[ATBAT]] | ||
| [[Anticoagulant Therapy With Bivalirudin To Assist In Pci 1St Inning Trial (Pci In Hit/Hitts)]] | | [[Anticoagulant Therapy With Bivalirudin To Assist In Pci 1St Inning Trial (Pci In Hit/Hitts)]] | ||
|- | |- | ||
| ATBC | | [[ATBC]] | ||
| [[Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study]] | | [[Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study]] | ||
|- | |- | ||
| ATHENA | | [[ATHENA]] | ||
| [[Effect Of Dronedarone On Cardiovascular Outcomes In High-Risk Patients With Atrial Fibrillation Or Atrial Flutter]] | | [[Effect Of Dronedarone On Cardiovascular Outcomes In High-Risk Patients With Atrial Fibrillation Or Atrial Flutter]] | ||
|- | |- | ||
| ATHEROMA | | [[ATHEROMA]] | ||
| [[Atorvastatin Therapy: Effects Of Reduction Of Macrophage Activity]] | | [[Atorvastatin Therapy: Effects Of Reduction Of Macrophage Activity]] | ||
|- | |- | ||
| ATICH | | [[ATICH]] | ||
| [[Antifibrinolytic Therapy In Acute Intracerebral Hemorrhage]] | | [[Antifibrinolytic Therapy In Acute Intracerebral Hemorrhage]] | ||
|- | |- | ||
| ATLANTIC | | [[ATLANTIC]] | ||
| [[Angina Treatments - - Lasers And Normal Therapies In Comparison]] | | [[Angina Treatments - - Lasers And Normal Therapies In Comparison]] | ||
|- | |- | ||
| ATLANTIS | | [[ATLANTIS]] | ||
| [[Alteplase Thrombolysis For Acute Noninterventional Therapy In Ischemic Stroke]] | | [[Alteplase Thrombolysis For Acute Noninterventional Therapy In Ischemic Stroke]] | ||
|- | |- | ||
| ATLAS | | [[ATLAS]] | ||
| [[Assessment Of Treatment With Lisinopril And Survival]] | | [[Assessment Of Treatment With Lisinopril And Survival]] | ||
|- | |- | ||
| ATLAS | | [[ATLAS]] | ||
| [[Acolysis During Treatment Of Lesions Affecting Saphenous Vein Bypass Grafts Assessment Of Treatment With Lisinopril And Survival]] | | [[Acolysis During Treatment Of Lesions Affecting Saphenous Vein Bypass Grafts Assessment Of Treatment With Lisinopril And Survival]] | ||
|- | |- | ||
| ATLAS - SVG | | [[ATLAS - SVG]] | ||
| [[Acolysis During Treatment Of Lesions Affecting Saphenous Vein Bypass Grafts]] | | [[Acolysis During Treatment Of Lesions Affecting Saphenous Vein Bypass Grafts]] | ||
|- | |- | ||
| ATLAST | | [[ATLAST]] | ||
| [[Antiplatelet Therapy Alone Versus Lovenox Plus Antiplatelet Therapy In Patients At Increased Risk Of Stent Thrombosis]] | | [[Antiplatelet Therapy Alone Versus Lovenox Plus Antiplatelet Therapy In Patients At Increased Risk Of Stent Thrombosis]] | ||
|- | |- | ||
| ATLAS-TIMI 46 | | [[ATLAS-TIMI 46]] | ||
| [[Anti-Xa Therapy To Lower Cardiovascular Events In Addition To Aspirin With Or Without Thienopyridine In Subjects With Acute Coronary Syndromes–Thrombolysis In Myocardial Infarction 46]] | | [[Anti-Xa Therapy To Lower Cardiovascular Events In Addition To Aspirin With Or Without Thienopyridine In Subjects With Acute Coronary Syndromes–Thrombolysis In Myocardial Infarction 46]] | ||
|- | |- | ||
| AtoZ | | [[AtoZ]] | ||
| [[Aggrastat To Zocor Study]] | | [[Aggrastat To Zocor Study]] | ||
|- | |- | ||
| ATRAMI | | [[ATRAMI]] | ||
| [[Baroreflex Sensitivity And Heart-Rate Variability In Prediction Of Total Cardiac Mortality After Myocardial Infarction. Atrami (Autonomic Tone And Reflexes After Myocardial Infarction) Investigators.]] | | [[Baroreflex Sensitivity And Heart-Rate Variability In Prediction Of Total Cardiac Mortality After Myocardial Infarction. Atrami (Autonomic Tone And Reflexes After Myocardial Infarction) Investigators.]] | ||
|- | |- | ||
| ATRIA | | [[ATRIA]] | ||
| [[The Anticoagulation And Risk Factors In Atrial Fibrillation Study]] | | [[The Anticoagulation And Risk Factors In Atrial Fibrillation Study]] | ||
|- | |- | ||
| ATRIA | | [[ATRIA]] | ||
| [[Anticoagulation And Risk Factors In Atrial Fibrillation ]] | | [[Anticoagulation And Risk Factors In Atrial Fibrillation ]] | ||
|- | |- | ||
| Atrial Arrhythmia Conversion Trial | | [[Atrial Arrhythmia Conversion Trial]] | ||
| [[Vernakalant Hydrochloride For Rapid Conversion Of Atrial Fibrillation]] | | [[Vernakalant Hydrochloride For Rapid Conversion Of Atrial Fibrillation]] | ||
|- | |- | ||
| ATS | | [[ATS]] | ||
| [[Amblyopia Treatment Study]] | | [[Amblyopia Treatment Study]] | ||
|- | |- | ||
| ATTACH | | [[ATTACH]] | ||
| [[Anti-Tnf Therapy Against Congestive Heart Failure Trial]] | | [[Anti-Tnf Therapy Against Congestive Heart Failure Trial]] | ||
|- | |- | ||
| ATTEST | | [[ATTEST]] | ||
| [[Atrial Therapy Efficacy And Safety Trial]] | | [[Atrial Therapy Efficacy And Safety Trial]] | ||
|- | |- | ||
| ATTRACT | | [[ATTRACT]] | ||
| [[Anti-Tnf Trial In Rheumatoid Arthritis With Ca2 Treatment ]] | | [[Anti-Tnf Trial In Rheumatoid Arthritis With Ca2 Treatment ]] | ||
|- | |- | ||
| AURORA | | [[AURORA]] | ||
| [[A Study To Evaluate The Use Of Rosuvastatin In Subjects On Regular Hemodialysis: An Assessment Of Survival And Cardiovascular Events]] | | [[A Study To Evaluate The Use Of Rosuvastatin In Subjects On Regular Hemodialysis: An Assessment Of Survival And Cardiovascular Events]] | ||
|- | |- | ||
| AVASIS | | [[AVASIS]] | ||
| [[Aspirin Versus Anticoagulants In Symptomatic Intracranial Stenosis]] | | [[Aspirin Versus Anticoagulants In Symptomatic Intracranial Stenosis]] | ||
|- | |- | ||
| AVERT | | [[AVERT]] | ||
| [[Atorvastatin Versus Revascularization Treatments]] | | [[Atorvastatin Versus Revascularization Treatments]] | ||
|- | |- | ||
| AVERT | | [[AVERT]] | ||
| [[Artificial Valve Endocarditis Reduction Trial]] | | [[Artificial Valve Endocarditis Reduction Trial]] | ||
|- | |- | ||
| AVID | | [[AVID]] | ||
| [[Antiarrhythmics Versus Implantable Defibrillators]] | | [[Antiarrhythmics Versus Implantable Defibrillators]] | ||
|- | |- | ||
| AVID | | [[AVID]] | ||
| [[Angiography Versus Intravascular Ultrasound-Directed Stent Placement]] | | [[Angiography Versus Intravascular Ultrasound-Directed Stent Placement]] | ||
|- | |- | ||
| AVID Electrical Storm Substudy | | [[AVID Electrical Storm Substudy]] | ||
| [[Electrical Storm Presages Nonsudden Death. The Antiarrhythmics Vs. Implantable Defibrillators (Avid) Trial]] | | [[Electrical Storm Presages Nonsudden Death. The Antiarrhythmics Vs. Implantable Defibrillators (Avid) Trial]] | ||
|- | |- | ||
| AVOID | | [[AVOID]] | ||
| [[Aliskiren In The Evaluation Of Proteinuria In Diabetes]] | | [[Aliskiren In The Evaluation Of Proteinuria In Diabetes]] | ||
|- | |- | ||
| AWESOME | | [[AWESOME]] | ||
| [[Angina With Extremely Serious Operative Mortality Evaluation]] | | [[Angina With Extremely Serious Operative Mortality Evaluation]] | ||
|- | |- | ||
| AZACS | | [[AZACS]] | ||
| [[Azithromycin In Acute Coronary Syndrome]] | | [[Azithromycin In Acute Coronary Syndrome]] | ||
|- | |- | ||
| BAATAF | | [[BAATAF]] | ||
| [[Boston Area Anticoagulation Trial For Atrial Fibrillation]] | | [[Boston Area Anticoagulation Trial For Atrial Fibrillation]] | ||
|- | |- | ||
| BACH | | [[BACH]] | ||
| [[Bach]] | | [[Bach]] | ||
|- | |- | ||
| BARI | | [[BARI]] | ||
| [[Bypass Angioplasty Revascularization Investigation]] | | [[Bypass Angioplasty Revascularization Investigation]] | ||
|- | |- | ||
| BARI 2D | | [[BARI 2D]] | ||
| [[Bypass Angioplasty Revascularization Investigation In Type 2 Diabetics]] | | [[Bypass Angioplasty Revascularization Investigation In Type 2 Diabetics]] | ||
|- | |- | ||
| BARS | | [[BARS]] | ||
| [[Beaumont Alcohol Restenosis Study]] | | [[Beaumont Alcohol Restenosis Study]] | ||
|- | |- | ||
| BASC | | [[BASC]] | ||
| [[Blood Pressure In Acute Stroke Collaboration]] | | [[Blood Pressure In Acute Stroke Collaboration]] | ||
|- | |- | ||
| BASEL | | [[BASEL]] | ||
| [[Brain Natriuretic Peptide For Acute Shortness Of Breath Evaluation: A Randomized Comparison]] | | [[Brain Natriuretic Peptide For Acute Shortness Of Breath Evaluation: A Randomized Comparison]] | ||
|- | |- | ||
| BASIS | | [[BASIS]] | ||
| [[Basel Antiarrhythmic Study Of Infarct Survival]] | | [[Basel Antiarrhythmic Study Of Infarct Survival]] | ||
|- | |- | ||
| BASKET | | [[BASKET]] | ||
| [[Basel Stent Cost-Effectiveness Trial]] | | [[Basel Stent Cost-Effectiveness Trial]] | ||
|- | |- | ||
| BASKET LATE | | [[BASKET LATE]] | ||
| [[Late Clinical Events Related To Late Stent Thrombosis After Stopping Clopidogrel]] | | [[Late Clinical Events Related To Late Stent Thrombosis After Stopping Clopidogrel]] | ||
|- | |- | ||
| BAT | | [[BAT]] | ||
| [[Bivalirudin Angioplasty Study]] | | [[Bivalirudin Angioplasty Study]] | ||
|- | |- | ||
| BATMAN | | [[BATMAN]] | ||
| [[Biodivysio 'Bat'Imastat Sv Stent Versus Balloon Angioplasty For The Reduction Of Restenosis In Small Coronary Arteries ]] | | [[Biodivysio 'Bat'Imastat Sv Stent Versus Balloon Angioplasty For The Reduction Of Restenosis In Small Coronary Arteries ]] | ||
|- | |- | ||
| BBC ONE | | [[BBC ONE]] | ||
| [[British Bifurcation Coronary Study: Old, New, And Evolving Strategies]] | | [[British Bifurcation Coronary Study: Old, New, And Evolving Strategies]] | ||
|- | |- | ||
| BBS—Cognitive Study | | [[BBS—Cognitive Study]] | ||
| [[Best Bypass Surgery—Cognitive Study]] | | [[Best Bypass Surgery—Cognitive Study]] | ||
|- | |- | ||
| BCAPS | | [[BCAPS]] | ||
| [[Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study]] | | [[Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study]] | ||
|- | |- | ||
| BCPT | | [[BCPT]] | ||
| [[Breast Cancer Prevention Trial]] | | [[Breast Cancer Prevention Trial]] | ||
|- | |- | ||
| BEACH | | [[BEACH]] | ||
| [[Boston Scientific Epi: A Carotid Stenting Trial For High-Risk Surgical Patients]] | | [[Boston Scientific Epi: A Carotid Stenting Trial For High-Risk Surgical Patients]] | ||
|- | |- | ||
| BEAT | | [[BEAT]] | ||
| [[Bucindolol Evaluation In Acute Myocardial Infarction Trial ]] | | [[Bucindolol Evaluation In Acute Myocardial Infarction Trial ]] | ||
|- | |- | ||
| BEAUTIFUL | | [[BEAUTIFUL]] | ||
| [[Morbidity-Mortality Evaluation Of The If Inhibitor Ivabradine In Patients With Coronary Disease And Left-Ventricular Dysfunction]] | | [[Morbidity-Mortality Evaluation Of The If Inhibitor Ivabradine In Patients With Coronary Disease And Left-Ventricular Dysfunction]] | ||
|- | |- | ||
| BECAIT | | [[BECAIT]] | ||
| [[Bezafibrate Coronary Atherosclerosis Intervention Trial]] | | [[Bezafibrate Coronary Atherosclerosis Intervention Trial]] | ||
|- | |- | ||
| BECAIT | | [[BECAIT]] | ||
| [[Bezafibrate Coronary Atherosclerosis Intervention Trial]] | | [[Bezafibrate Coronary Atherosclerosis Intervention Trial]] | ||
|- | |- | ||
| BELLES | | [[BELLES]] | ||
| [[Beyond Endorsed Lipid Lowering With Ebt Scanning]] | | [[Beyond Endorsed Lipid Lowering With Ebt Scanning]] | ||
|- | |- | ||
| BELLES | | [[BELLES]] | ||
| [[Beyond Endorsed Lipid Lowering With Ebct Scannings]] | | [[Beyond Endorsed Lipid Lowering With Ebct Scannings]] | ||
|- | |- | ||
| BENEDICT | | [[BENEDICT]] | ||
| [[Bergamo Nephrologic Diabetes Complications Trial]] | | [[Bergamo Nephrologic Diabetes Complications Trial]] | ||
|- | |- | ||
| BENEFiT | | [[BENEFiT]] | ||
| [[Bosentan Effects In Inoperable Forms Of Chronic Thromboembolic Pulmonary Hypertension]] | | [[Bosentan Effects In Inoperable Forms Of Chronic Thromboembolic Pulmonary Hypertension]] | ||
|- | |- | ||
| BENEFIT | | [[BENEFIT]] | ||
| [[Betaferon (Betaseron In U.S.) In Newly Emerging Ms For Initial Treatment Information]] | | [[Betaferon (Betaseron In U.S.) In Newly Emerging Ms For Initial Treatment Information]] | ||
|- | |- | ||
| BENESTENT | | [[BENESTENT]] | ||
| [[Belgium Netherlands Stent]] | | [[Belgium Netherlands Stent]] | ||
|- | |- | ||
| BENESTENT I | | [[BENESTENT I]] | ||
| [[Belgian-Netherlands Stent Study (I)]] | | [[Belgian-Netherlands Stent Study (I)]] | ||
|- | |- | ||
| BENESTENT II | | [[BENESTENT II]] | ||
| [[Belgian-Netherlands Stent Study II (Pilot)]] | | [[Belgian-Netherlands Stent Study II (Pilot)]] | ||
|- | |- | ||
| BERT | | [[BERT]] | ||
| [[Beta Energy Restenosis Trial - 1]] | | [[Beta Energy Restenosis Trial - 1]] | ||
|- | |- | ||
| BERT | | [[[BERT]] | ||
| [[Beta Energy Restenosis Trial ]] | | [[Beta Energy Restenosis Trial ]] | ||
|- | |- | ||
| BESMART | | [[BESMART]] | ||
| [[Bestent In Small Arteries Trial]] | | [[Bestent In Small Arteries Trial]] | ||
|- | |- | ||
| BESMART | | [[BESMART]] | ||
| [[Bestent In Small Arteries]] | | [[Bestent In Small Arteries]] | ||
|- | |- | ||
| BESSAMI | | [[BESSAMI]] | ||
| [[Berlin Stent Study In Acute Myocardial Infarction]] | | [[Berlin Stent Study In Acute Myocardial Infarction]] | ||
|- | |- | ||
| BEST | | [[BEST]] | ||
| [[Beta Blocker Evaluation Of Survival Trial]] | | [[Beta Blocker Evaluation Of Survival Trial]] | ||
|- | |- | ||
| BEST | | [[BEST]] | ||
| [[Balloon Equivalent To Stent Trial]] | | [[Balloon Equivalent To Stent Trial]] | ||
|- | |- | ||
| BEST | | [[BEST]] | ||
| [[Beta-Blocker Evaluation Of Survival Trial ]] | | [[Beta-Blocker Evaluation Of Survival Trial ]] | ||
|- | |- | ||
| BEST-ICD | | [[BEST-ICD]] | ||
| [[Beta-Blocker Evaluation Of Survival Trial Plus Icd]] | | [[Beta-Blocker Evaluation Of Survival Trial Plus Icd]] | ||
|- | |- | ||
| BETA WRIST | | [[BETA WRIST]] | ||
| [[Washington Radiation For In-Stent Restenosis Trial]] | | [[Washington Radiation For In-Stent Restenosis Trial]] | ||
|- | |- | ||
| BETACATH | | [[BETACATH]] | ||
| [[Clinical And Angiographic Outcomes After Use Of Sr-90 Beta Radiation For The Treatment Of De Novo And Restenotic Coronary Lesions]] | | [[Clinical And Angiographic Outcomes After Use Of Sr-90 Beta Radiation For The Treatment Of De Novo And Restenotic Coronary Lesions]] | ||
|- | |- | ||
| BETTER | | [[BETTER]] | ||
| [[Beta Radiation Trial To Eliminate Restenosis]] | | [[Beta Radiation Trial To Eliminate Restenosis]] | ||
|- | |- | ||
| BETTER | | [[BETTER]] | ||
| [[Beta Radiation Trial To Eliminate Restenosis ]] | | [[Beta Radiation Trial To Eliminate Restenosis ]] | ||
|- | |- | ||
| BHACAS | | [[BHACAS]] | ||
| [[Early And Midterm Outcome After Off-Pump And On-Pump Surgery In Beating Heart Against Cardioplegic Arrest Studies (Bhacas 1 And 2): A Pooled Analysis Of Two Randomised Controlled Trials.]] | | [[Early And Midterm Outcome After Off-Pump And On-Pump Surgery In Beating Heart Against Cardioplegic Arrest Studies (Bhacas 1 And 2): A Pooled Analysis Of Two Randomised Controlled Trials.]] | ||
|- | |- | ||
| BHACAS | | [BHACAS]] | ||
| [[Beating Heart Against Cardioplegic Arrest Studies]] | | [[Beating Heart Against Cardioplegic Arrest Studies]] | ||
|- | |- | ||
| BHAT | | [[BHAT]] | ||
| [[Beta Blocker Heart Attack Trial]] | | [[Beta Blocker Heart Attack Trial]] | ||
|- | |- | ||
| BiCard | | [[BiCard]] | ||
| [[Biphasic Vs. Monophasic Shock Waveform For Conversion Of Atrial Fibrillation. The Results Of An International Randomized, Double-Blind Multicenter Trial]] | | [[Biphasic Vs. Monophasic Shock Waveform For Conversion Of Atrial Fibrillation. The Results Of An International Randomized, Double-Blind Multicenter Trial]] | ||
|- | |- | ||
| BICC | | [[BICC]] | ||
| [[Beta-Interferon In Chronic Viral Cardiomyopathy]] | | [[Beta-Interferon In Chronic Viral Cardiomyopathy]] | ||
|- | |- | ||
| BIP | | [[BIP]] | ||
| [[Bezafibrate Infarction Prevention Study]] | | [[Bezafibrate Infarction Prevention Study]] | ||
|- | |- | ||
| BIP | | [[BIP]] | ||
| [[Bezafibrate Infarction Prevention]] | | [[Bezafibrate Infarction Prevention]] | ||
|- | |- | ||
| BIRD | | [[BIRD]] | ||
| [[ Bolus Versus Infusion In Rescupase (Saruplase) Development]] | | [[ Bolus Versus Infusion In Rescupase (Saruplase) Development]] | ||
|- | |- | ||
| BLIND-DATE | | [[BLIND-DATE]] | ||
| [[Blinded Withdrawal Of Deprenyl In The Datatop Extension Trial]] | | [[Blinded Withdrawal Of Deprenyl In The Datatop Extension Trial]] | ||
|- | |- | ||
| BLOSS | | [[BLOSS]] | ||
| [[Beta Blocker Length Of Stay Study]] | | [[Beta Blocker Length Of Stay Study]] | ||
|- | |- | ||
| BNP | | [[BNP]] | ||
| [[Breathing Not Properly]] | | [[Breathing Not Properly]] | ||
|- | |- | ||
| BOAT | | [[BOAT]] | ||
| [[Balloon Angioplasty Versus Optimal Atherectomy Trial]] | | [[Balloon Angioplasty Versus Optimal Atherectomy Trial]] | ||
|- | |- | ||
| Bogalusa | | [[Bogalusa]] | ||
| [[Bogalusa Heart Study]] | | [[Bogalusa Heart Study]] | ||
|- | |- | ||
| BOOST | | [[BOOST]] | ||
| [[Bone Marrow Transfer To Enhance St-Elevation Infarct Regeneration]] | | [[Bone Marrow Transfer To Enhance St-Elevation Infarct Regeneration]] | ||
|- | |- | ||
| BPAV | | [[[BPAV]] | ||
| [[Balloon Prophylaxis Of Aneurysmal Vasospasm]] | | [[Balloon Prophylaxis Of Aneurysmal Vasospasm]] | ||
|- | |- | ||
| BRAINS | | [[BRAINS]] | ||
| [[Bayer Randomized Acute Ischemia Neuroprotectant Study]] | | [[Bayer Randomized Acute Ischemia Neuroprotectant Study]] | ||
|- | |- | ||
| BRAVE | | [[BRAVE]] | ||
| [[Bavarian Reperfusion Alternatives Evaluation]] | | [[Bavarian Reperfusion Alternatives Evaluation]] | ||
|- | |- | ||
| BRAVE-2 | | [[BRAVE-2]] | ||
| [[Beyond 12 Hours Reperfusion Alternative Evaluation Trial]] | | [[Beyond 12 Hours Reperfusion Alternative Evaluation Trial]] | ||
|- | |- | ||
| BRAVE-3 | | [[BRAVE-3]] | ||
| [[Value Of Abciximab In Patients With Ami Undergoing Pci After High Loading Dose Of Clopidogrel Pretreatment]] | | [[Value Of Abciximab In Patients With Ami Undergoing Pci After High Loading Dose Of Clopidogrel Pretreatment]] | ||
|- | |- | ||
| BRAVO | | [[BRAVO]] | ||
| [[Blockade Of The Glycoprotein IIb/IIia Receptor To Avoid Vascular Occlusion]] | | [[Blockade Of The Glycoprotein IIb/IIia Receptor To Avoid Vascular Occlusion]] | ||
|- | |- | ||
| BRAVO | | [[BRAVO]] | ||
| [[Beta Radiation For Treatment Of Arteriovenous Graft Outflow Sponsor:]] | | [[Beta Radiation For Treatment Of Arteriovenous Graft Outflow Sponsor:]] | ||
|- | |- | ||
| BREATHE-1 | | [[BREATHE-1]] | ||
| [[Bosentan (Tracleer): Randomized Trial Of Endothelin Receptor Antagonist Therapy For Pulmonary Hypertension]] | | [[Bosentan (Tracleer): Randomized Trial Of Endothelin Receptor Antagonist Therapy For Pulmonary Hypertension]] | ||
|- | |- | ||
| BRIDGE | | [[BRIDGE]] | ||
| [[Beta-Radiation Investigation With Direct Stenting And Galileo In Europe]] | | [[Beta-Radiation Investigation With Direct Stenting And Galileo In Europe]] | ||
|- | |- | ||
| BRIE | | [[BRIE]] | ||
| [[Beta Radiation In Europe]] | | [[Beta Radiation In Europe]] | ||
|- | |- | ||
| BRIEF-PCI | | [[BRIEF-PCI]] | ||
| [[Brief Infusion Of Eptifibatide Following Percutaneous Coronary Intervention]] | | [[Brief Infusion Of Eptifibatide Following Percutaneous Coronary Intervention]] | ||
|- | |- | ||
| BRILLIANT | | [[BRILLIANT]] | ||
| [[Batimastat (Bb-94) Antirestenosis Trial Utilizing The Biodivysio Local Drug Delivery Pc Stent ]] | | [[Batimastat (Bb-94) Antirestenosis Trial Utilizing The Biodivysio Local Drug Delivery Pc Stent ]] | ||
|- | |- | ||
| BRITE | | [[BRITE]] | ||
| [[Beta Radiation To Reduce In-Stent Restenosis]] | | [[Beta Radiation To Reduce In-Stent Restenosis]] | ||
|- | |- | ||
| BRITE | | [[BRITE]] | ||
| [[Beta Radiation To Reduce In-Stent Restenosis ]] | | [[Beta Radiation To Reduce In-Stent Restenosis ]] | ||
|- | |- | ||
| BRITE II | | [[BRITE II]] | ||
| [[Beta Radiation To Reduce In-Stent Restenosis II]] | | [[Beta Radiation To Reduce In-Stent Restenosis II]] | ||
|- | |- | ||
| BRITE-SVG | | [[BRITE-SVG]] | ||
| [[Beta Radiation To Reduce In-Stent Restenosis In Saphenous Vein Grafts]] | | [[Beta Radiation To Reduce In-Stent Restenosis In Saphenous Vein Grafts]] | ||
|- | |- | ||
| BRITE-SVG | | [[BRITE-SVG]] | ||
| [[Beta Radiation To Reduce In-Stent Restenosis For Saphenous Vein Bypass Grafts]] | | [[Beta Radiation To Reduce In-Stent Restenosis For Saphenous Vein Bypass Grafts]] | ||
|- | |- | ||
| CABERNET | | [[CABERNET]] | ||
| [[A Prospective Registry Of Carotid Stenting With The Nexstent And Distal Protection With The Filterwire Ex In High Risk Patients]] | | [[A Prospective Registry Of Carotid Stenting With The Nexstent And Distal Protection With The Filterwire Ex In High Risk Patients]] | ||
|- | |- | ||
| CABERNET | | [[CABERNET]] | ||
| [[Carotid Artery Revascularization Using The Boston Scientific Epi Filterwire Ex And The Endotex Nexstent]] | | [[Carotid Artery Revascularization Using The Boston Scientific Epi Filterwire Ex And The Endotex Nexstent]] | ||
|- | |- | ||
| CABG PATCH | | [[CABG PATCH]] | ||
| [[The Coronary Artery Bypass Graft Patch Trial]] | | [[The Coronary Artery Bypass Graft Patch Trial]] | ||
|- | |- | ||
| CABG Patch Cardioplegia Substudy | | [[CABG Patch Cardioplegia Substudy]] | ||
| [[Does Cardioplegia Type Affect Outcome And Survival In Patients With Advanced Left Ventricular Dysfunction? Results From The Cabg Patch Tria]] | | [[Does Cardioplegia Type Affect Outcome And Survival In Patients With Advanced Left Ventricular Dysfunction? Results From The Cabg Patch Tria]] | ||
|- | |- | ||
| CABRI | | [[CABRI]] | ||
| [[Coronary Angioplasty Versus Bypass Revascularization Investigation]] | | [[Coronary Angioplasty Versus Bypass Revascularization Investigation]] | ||
|- | |- | ||
| CACAF | | [[CACAF]] | ||
| [[Catheter Ablation For The Cure Of Atrial Fibrillation Study]] | | [[Catheter Ablation For The Cure Of Atrial Fibrillation Study]] | ||
|- | |- | ||
| CACHET | | [[CACHET]] | ||
| [[Comparison Of Abciximab Complications With Hirulog (Angiomax As Of 1999) Ischemic Events Trial]] | | [[Comparison Of Abciximab Complications With Hirulog (Angiomax As Of 1999) Ischemic Events Trial]] | ||
|- | |- | ||
| CACTUS | | [[CACTUS]] | ||
| [[Coronary Bifurcations: Application Of The Crushing Technique Using Sirolimus-Eluting Stents]] | | [[Coronary Bifurcations: Application Of The Crushing Technique Using Sirolimus-Eluting Stents]] | ||
|- | |- | ||
| CADILLAC | | [[CADILLAC]] | ||
| [[Controlled Abciximab And Device Investigation To Lower Late Angioplasty Complications]] | | [[Controlled Abciximab And Device Investigation To Lower Late Angioplasty Complications]] | ||
|- | |- | ||
| CADILLAC | | [[CADILLAC]] | ||
| [[Controlled Abciximab (Reopro) And Device Investigation To Lower Late Angioplasty Complications]] | | [[Controlled Abciximab (Reopro) And Device Investigation To Lower Late Angioplasty Complications]] | ||
|- | |- | ||
| CAESAR | | [[CAESAR]] | ||
| [[Canada, Australia, Europe, South Africa Aids Study ]] | | [[Canada, Australia, Europe, South Africa Aids Study ]] | ||
|- | |- | ||
| CAFA | | [[CAFA]] | ||
| [[Canadian Atrial Fibrillation Anticoagulation Study]] | | [[Canadian Atrial Fibrillation Anticoagulation Study]] | ||
|- | |- | ||
| CAFE | | [[CAFE]] | ||
| [[Conduit Artery Function Evaluation]] | | [[Conduit Artery Function Evaluation]] | ||
|- | |- | ||
| CALM | | [[CALM]] | ||
| [[Candesartan And Lisinopril Microalbuminuria (Calm) Study]] | | [[Candesartan And Lisinopril Microalbuminuria (Calm) Study]] | ||
|- | |- | ||
| CALM | | [[CALM]] | ||
| [[Candesartan And Lisinopril Microalbuminuria Study]] | | [[Candesartan And Lisinopril Microalbuminuria Study]] | ||
|- | |- | ||
| CALM-PD | | [[CALM-PD]] | ||
| [[Comparison Of The Agonist Pramipexole Vs. Levodopa On Motor Complications In Parkinson Disease]] | | [[Comparison Of The Agonist Pramipexole Vs. Levodopa On Motor Complications In Parkinson Disease]] | ||
|- | |- | ||
| CALYPSO | | [[CALYPSO]] | ||
| [[Cylexin As An Adjunct To Lytic Therapy To Prevent Superoxide Reflow Injury]] | | [[Cylexin As An Adjunct To Lytic Therapy To Prevent Superoxide Reflow Injury]] | ||
|- | |- | ||
| CAMELOT | | [[CAMELOT]] | ||
| [[Comparison Of Amlodipine Vs Enalapril To Limit Occurrences Of Thrombosis]] | | [[Comparison Of Amlodipine Vs Enalapril To Limit Occurrences Of Thrombosis]] | ||
|- | |- | ||
| CAMELOT | | [[CAMELOT]] | ||
| [[Comparison Of Amlodipine Versus Enalapril (Lipitor) To Limit Occurrences Of Thrombosis]] | | [[Comparison Of Amlodipine Versus Enalapril (Lipitor) To Limit Occurrences Of Thrombosis]] | ||
|- | |- | ||
| CAMEO | | [[CAMEO]] | ||
| [[Cerebral Aneurysm Multicenter European]] | | [[Cerebral Aneurysm Multicenter European]] | ||
|- | |- | ||
| CAMIAT | | [[CAMIAT]] | ||
| [[Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (Pilot)]] | | [[Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (Pilot)]] | ||
|- | |- | ||
| CANDLE | | [[CANDLE]] | ||
| [[Candesartan Versus Losartan Efficacy Comparison Study Group]] | | [[Candesartan Versus Losartan Efficacy Comparison Study Group]] | ||
|- | |- | ||
| CANDLE | | [[CANDLE]] | ||
| [[Candesartan Versus Losartan Efficacy Comparison ]] | | [[Candesartan Versus Losartan Efficacy Comparison ]] | ||
|- | |- | ||
| Cangrelor during PCI | | [[Cangrelor during PCI]] | ||
| [[Cangrelor During Percutaneous Coronary Intervention]] | | [[Cangrelor During Percutaneous Coronary Intervention]] | ||
|- | |- | ||
| CANPAP | | [[CANPAP]] | ||
| [[Continuous Positive Airway Pressure For Heart Failure Patients With Central Sleep Apnea]] | | [[Continuous Positive Airway Pressure For Heart Failure Patients With Central Sleep Apnea]] | ||
|- | |- | ||
| CAPARES | | [[CAPARES]] | ||
| [[Coronary Angioplasty Amlodipine Restenosis Study]] | | [[Coronary Angioplasty Amlodipine Restenosis Study]] | ||
|- | |- | ||
| CAPARES | | [[CAPARES]] | ||
| [[Coronary Angioplasty Amlodipine Restenosis Study]] | | [[Coronary Angioplasty Amlodipine Restenosis Study]] | ||
|- | |- | ||
| CAPE II | | [[CAPE II]] | ||
| [[Medical Treatment Of Myocardial Ischemia In Coronary Artery Disease: Effect Of Drug Regime And Irregular Dosing In The Cape II Trial]] | | [[Medical Treatment Of Myocardial Ischemia In Coronary Artery Disease: Effect Of Drug Regime And Irregular Dosing In The Cape II Trial]] | ||
|- | |- | ||
| CAPITAL AMI | | [[CAPITAL AMI]] | ||
| [[Combined Angioplasty And Pharmacological Intervention Versus Thrombolytics Alone In Acute Myocardial Infarction]] | | [[Combined Angioplasty And Pharmacological Intervention Versus Thrombolytics Alone In Acute Myocardial Infarction]] | ||
|- | |- | ||
| CAPPP | | [[CAPPP]] | ||
| [[Captopril Prevention Project]] | | [[Captopril Prevention Project]] | ||
|- | |- | ||
| CAPRICORN | | [[CAPRICORN]] | ||
| [[Carvedilol Post-Infarct Survival Controlled Evaluation]] | | [[Carvedilol Post-Infarct Survival Controlled Evaluation]] | ||
|- | |- | ||
| CAPRICORN | | [[CAPRICORN]] | ||
| [[Carvedilol Post Infarction Survival Control In Left Ventricular Dysfunction]] | | [[Carvedilol Post Infarction Survival Control In Left Ventricular Dysfunction]] | ||
|- | |- | ||
| CAPRIE | | [[CAPRIE]] | ||
| [[Clopidogrel Versus Aspirin In Patients At Risk Of Ischaemic Events]] | | [[Clopidogrel Versus Aspirin In Patients At Risk Of Ischaemic Events]] | ||
|- | |- | ||
| CAPRIE | | [[CAPRIE]] | ||
| [[Clopidogrel Versus Aspirin In Patients At Risk Of Ischemic Events ]] | | [[Clopidogrel Versus Aspirin In Patients At Risk Of Ischemic Events ]] | ||
|- | |- | ||
| CAPS | | [[CAPS]] | ||
| [[The Cardiac Arrhythmic Pilot Study]] | | [[The Cardiac Arrhythmic Pilot Study]] | ||
|- | |- | ||
| CAPT | | [[CAPT]] | ||
| [[Complications Of Amd (Age-Related Macular Degeneration) Prevention Trial]] | | [[Complications Of Amd (Age-Related Macular Degeneration) Prevention Trial]] | ||
|- | |- | ||
| CAPTEN | | [[CAPTEN]] | ||
| [[Captopril After Thrombolysis Trial ]] | | [[Captopril After Thrombolysis Trial ]] | ||
|- | |- | ||
| CAPTIM | | [[CAPTIM]] | ||
| [[Comparison Of Angioplasty And Prehospital Thrombolysis In Acute Myocardial Infarction]] | | [[Comparison Of Angioplasty And Prehospital Thrombolysis In Acute Myocardial Infarction]] | ||
|- | |- | ||
| [[CAPTIN]] | |||
| [[ | |||
| [[Captopril Plus Tissue Plasminogen Activator Following Acute Myocardial Infarction]] | | [[Captopril Plus Tissue Plasminogen Activator Following Acute Myocardial Infarction]] | ||
|- | |- | ||
| CAPTIVATE | | [[CAPTIVATE]] | ||
| [[Carotid Atherosclerosis Progression Trial Investigating Vascular Acat Inhibition Treatment Effects]] | | [[Carotid Atherosclerosis Progression Trial Investigating Vascular Acat Inhibition Treatment Effects]] | ||
|- | |- | ||
| CAPTIVE | | [[CAPTIVE]] | ||
| [[A Prospective, Randomized, Controlled Trial Of Distal Protection With The Third Generation Mednova Emboshield Compared To The Guardwire Or Filterwire]] | | [[A Prospective, Randomized, Controlled Trial Of Distal Protection With The Third Generation Mednova Emboshield Compared To The Guardwire Or Filterwire]] | ||
|- | |- | ||
| CAPTURE | | [[CAPTURE]] | ||
| [[Chimeric 7E3 Antiplatelet Therapy In Unstable Angina Refractory To Standard Treatment]] | | [[Chimeric 7E3 Antiplatelet Therapy In Unstable Angina Refractory To Standard Treatment]] | ||
|- | |- | ||
| CAPTURE | | [[CAPTURE]] | ||
| [[C7E3 Antiplatelet Therapy In Unstable Refractory Angina]] | | [[C7E3 Antiplatelet Therapy In Unstable Refractory Angina]] | ||
|- | |- | ||
| CAPTURE Registry | | [[CAPTURE Registry]] | ||
| [[Carotid Acculink/Accunet Post-Approval Trial To Uncover Unanticipated Or Rare Events Registry]] | | [[Carotid Acculink/Accunet Post-Approval Trial To Uncover Unanticipated Or Rare Events Registry]] | ||
|- | |- | ||
| CARAT | | [[CARAT]] | ||
| [[Coronary Angioplasty And Rotational Atherectomy Trial]] | | [[Coronary Angioplasty And Rotational Atherectomy Trial]] | ||
|- | |- | ||
| [[CARDIA]] | |||
| [[ | |||
| [[Coronary Artery Risk Development In Young Adults]] | | [[Coronary Artery Risk Development In Young Adults]] | ||
|- | |- | ||
| CARDia | | [[CARDia]] | ||
| [[Coronary Artery Revascularization In Diabetes Trial]] | | [[Coronary Artery Revascularization In Diabetes Trial]] | ||
|- | |- | ||
| CARDINAL | | [[CARDINAL]] | ||
| [[Complement And Reduction Of Infarct Size After Angioplasty Or Lytics]] | | [[Complement And Reduction Of Infarct Size After Angioplasty Or Lytics]] | ||
|- | |- | ||
| [[CARDS]] | |||
| [[ | |||
| [[Collaborative Atorvastatin (Lipitor) And Diabetes Study]] | | [[Collaborative Atorvastatin (Lipitor) And Diabetes Study]] | ||
|- | |- | ||
| CARE | | [[CARE]] | ||
| [[Cardiac Angiography In Renally Impaired Patients]] | | [[Cardiac Angiography In Renally Impaired Patients]] | ||
|- | |- | ||
| CARE | | [[CARE]] | ||
| [[Cholesterol And Recurrent Events]] | | [[Cholesterol And Recurrent Events]] | ||
|- | |- | ||
| CARE | | [[CARE]] | ||
| [[Calcium Antagonist In Reperfusion Cholesterol And Recurrent Events Carvedilol Atherectomy Restenosis ]] | | [[Calcium Antagonist In Reperfusion Cholesterol And Recurrent Events Carvedilol Atherectomy Restenosis ]] | ||
|- | |- | ||
| CARE-HD | | [[CARE-HD]] | ||
| [[Coenzyme Q10 And Remacemide: Evaluation In Huntington Disease]] | | [[Coenzyme Q10 And Remacemide: Evaluation In Huntington Disease]] | ||
|- | |- | ||
| CARE-HF | | [[CARE-HF]] | ||
| [[Cardiac Resynchronization Heart Failure Study]] | | [[Cardiac Resynchronization Heart Failure Study]] | ||
|- | |- | ||
| CARE-HF | | [[CARE-HF]] | ||
| [[Cardiac Resynchronization - Heart Failure European Complement To U.S./Canada Miracle Study]] | | [[Cardiac Resynchronization - Heart Failure European Complement To U.S./Canada Miracle Study]] | ||
|- | |- | ||
| CARESS | | [[CARESS]] | ||
| [[Clopidogrel And Aspirin For Reduction Of Emboli In Symptomatic Carotid Stenosis]] | | [[Clopidogrel And Aspirin For Reduction Of Emboli In Symptomatic Carotid Stenosis]] | ||
|- | |- | ||
| CARESS-in-AMI: 30-Day and 1-Year Results | | [[CARESS-in-AMI: 30-Day and 1-Year Results]] | ||
| [[Combined Abciximab Reteplase Stent Study In Acute Myocardial Infarction]] | | [[Combined Abciximab Reteplase Stent Study In Acute Myocardial Infarction]] | ||
|- | |- | ||
| CARET | | [[CARET]] | ||
| [[The Beta Carotene And Retinol Efficacy Trial]] | | [[The Beta Carotene And Retinol Efficacy Trial]] | ||
|- | |- | ||
| CARIBE | | [[CARIBE]] | ||
| [[Carvedilol Insuficiencia Cardiaca (Heart Failure) Beta-Receptor]] | | [[Carvedilol Insuficiencia Cardiaca (Heart Failure) Beta-Receptor]] | ||
|- | |- | ||
| [[CARISA]] | |||
| [[ | |||
| [[Combination Assessment Of Ranolazine In Stable Angina ]] | | [[Combination Assessment Of Ranolazine In Stable Angina ]] | ||
|- | |- | ||
| CARMEN | | [[CARMEN]] | ||
| [[The Carvedilol And Ace-Inhibitor Remodeling Mild Heart Failure Evaluation Trial]] | | [[The Carvedilol And Ace-Inhibitor Remodeling Mild Heart Failure Evaluation Trial]] | ||
|- | |- | ||
| CARMEN | | [[CARMEN]] | ||
| [[Carvedilol Ace Inhibitors Remodelling Mild Heart Failure Evaluation]] | | [[Carvedilol Ace Inhibitors Remodelling Mild Heart Failure Evaluation]] | ||
|- | |- | ||
| CARP | | [[CARP]] | ||
| [[Coronary Artery Revascularization Prophylaxis]] | | [[Coronary Artery Revascularization Prophylaxis]] | ||
|- | |- | ||
| CARS | | [[CARS]] | ||
| [[Coumadin Aspirin Reinfarction Study]] | | [[Coumadin Aspirin Reinfarction Study]] | ||
|- | |- | ||
| CART | | [[CART]] | ||
| [[Canadian Antioxidant Restenosis Trial]] | | [[Canadian Antioxidant Restenosis Trial]] | ||
|- | |- | ||
| [[CARVEDILOL]] | |||
| [[ | |||
| [[The Effects Of Carvedilol On Morbidity And Mortality In Patients With Chronic Heart Failure]] | | [[The Effects Of Carvedilol On Morbidity And Mortality In Patients With Chronic Heart Failure]] | ||
|- | |- | ||
| CASCADE | | [[CASCADE]] | ||
| [[Cardiac Arrest In Seattle: Conventional Versus Amiodarone Drug Evaluation Study]] | | [[Cardiac Arrest In Seattle: Conventional Versus Amiodarone Drug Evaluation Study]] | ||
|- | |- | ||
| CASES | | [[CASES]] | ||
| [[Canadian Activase For Stroke Effectiveness Study]] | | [[Canadian Activase For Stroke Effectiveness Study]] | ||
|- | |- | ||
| [[CASH]] | |||
| [[ | |||
| [[Cardiac Arrest Study-Hamburg]] | | [[Cardiac Arrest Study-Hamburg]] | ||
|- | |- | ||
| CASIS | | [[CASIS]] | ||
| [[Canadian Amlodipine/Atenolol In Silent Ischemia Study]] | | [[Canadian Amlodipine/Atenolol In Silent Ischemia Study]] | ||
|- | |- | ||
| CASS | | [[CASS]] | ||
| [[Coronary Artery Surgery Study]] | | [[Coronary Artery Surgery Study]] | ||
|- | |- | ||
| CAST | | [[CAST]] | ||
| [[The Cardiac Arrhythmia Suppression Trial]] | | [[The Cardiac Arrhythmia Suppression Trial]] | ||
|- | |- | ||
| CAST | | [[CAST]] | ||
| [[Cardiac Arrhythmia Suppression Trial ]] | | [[Cardiac Arrhythmia Suppression Trial ]] | ||
|- | |- | ||
| CASTEMI | | [[CASTEMI]] | ||
| [[Calderet In St Elevation Myocardial Infarction]] | | [[Calderet In St Elevation Myocardial Infarction]] | ||
|- | |- | ||
| CAST-II | | [[CAST-II]] | ||
| [[The Cardiac Arrhythmia Suppression Trial II]] | | [[The Cardiac Arrhythmia Suppression Trial II]] | ||
|- | |- | ||
| CASTLE | | [[[CASTLE]] | ||
| [[Candesartan Amlodipine Study Of Tolerability And Efficacy]] | | [[Candesartan Amlodipine Study Of Tolerability And Efficacy]] | ||
|- | |- | ||
| CAT | | [[CAT]] | ||
| [[Cardiomyopathy Trial]] | | [[Cardiomyopathy Trial]] | ||
|- | |- | ||
| CAT | | [[CAT]] | ||
| [[Chinese Ace Inhibitor In Acute Myocardial Infarction Trial Cardiomyopathy Trial]] | | [[Chinese Ace Inhibitor In Acute Myocardial Infarction Trial Cardiomyopathy Trial]] | ||
|- | |- | ||
| CATAPULT | | [[CATAPULT]] | ||
| [[Cisplatin And Tirapazamine In Subjects With Advanced Previously Untreated Non–Small Cell Lung Tumors]] | | [[Cisplatin And Tirapazamine In Subjects With Advanced Previously Untreated Non–Small Cell Lung Tumors]] | ||
|- | |- | ||
| Cathedia Study | | [[Cathedia Study]] | ||
| [[Femoral Vs. Jugular Venous Catheterization And Risk Of Nosocomial Events In Adults Requiring Acute Renal Replacement Therapy]] | | [[Femoral Vs. Jugular Venous Catheterization And Risk Of Nosocomial Events In Adults Requiring Acute Renal Replacement Therapy]] | ||
|- | |- | ||
| CATIE | | [[CATIE]] | ||
| [[Clinical Antipsychotic Trials Of Intervention Effectiveness]] | | [[Clinical Antipsychotic Trials Of Intervention Effectiveness]] | ||
|- | |- | ||
| CATS | | [[CATS]] | ||
| [[Canadian American Ticlopidine Study]] | | [[Canadian American Ticlopidine Study]] | ||
|- | |- | ||
| CATS | | [[CATS]] | ||
| [[Captopril And Thrombolysis Study]] | | [[Captopril And Thrombolysis Study]] | ||
|- | |- | ||
| CAVATAS | | [[CAVATAS]] | ||
| [[Endovascular Versus Surgical Treatment In Patients With Carotid Stenosis In The Carotid And Vertebral Artery Transluminal Angioplasty Study (Cavatas)]] | | [[Endovascular Versus Surgical Treatment In Patients With Carotid Stenosis In The Carotid And Vertebral Artery Transluminal Angioplasty Study (Cavatas)]] | ||
|- | |- | ||
| CAVATAS | | [[CAVATAS]] | ||
| [[Carotid And Vertebral Artery Transluminal Angioplasty Study]] | | [[Carotid And Vertebral Artery Transluminal Angioplasty Study]] | ||
|- | |- | ||
| CAVEAT I | | [[CAVEAT I]] | ||
| [[Coronary Angioplasty Versus Excisional Atherectomy Trial I]] | | [[Coronary Angioplasty Versus Excisional Atherectomy Trial I]] | ||
|- | |- | ||
| CAVEAT II | | [[CAVEAT II]] | ||
| [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | | [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | ||
|- | |- | ||
| CBT-CD | | [CBT-CD]] | ||
| [[Cognitive Behavior Therapy For The Chronic Depressions]] | | [[Cognitive Behavior Therapy For The Chronic Depressions]] | ||
|- | |- | ||
| CCAT | | [[CCAT]] | ||
| [[Canadian Coronary Atherectomy Trial]] | | [[Canadian Coronary Atherectomy Trial]] | ||
|- | |- | ||
| CCP | | [[CCP]] | ||
| [[The Cooperative Cardiovascular Project]] | | [[The Cooperative Cardiovascular Project]] | ||
|- | |- | ||
| CCS-1 | | [[CCS-1]] | ||
| [[Chinese Cardiac Study]] | | [[Chinese Cardiac Study]] | ||
|- | |- | ||
| CDP | | [[CDP]] | ||
| [[Coronary Drug Project]] | | [[Coronary Drug Project]] | ||
|- | |- | ||
| CEDARS | | [[CEDARS]] | ||
| [[Comprehensive Evaluation Of Defibrillators And Resuscitative Shock]] | | [[Comprehensive Evaluation Of Defibrillators And Resuscitative Shock]] | ||
|- | |- | ||
| CELL | | [[CELL]] | ||
| [[Cost Effectiveness Of Lipid Lowering Study]] | | [[Cost Effectiveness Of Lipid Lowering Study]] | ||
|- | |- | ||
| CEOS | | [[CEOS]] | ||
| [[Congenital Esotropia Observational Study]] | | [[Congenital Esotropia Observational Study]] | ||
|- | |- | ||
| CHAMP | | [[CHAMP]] | ||
| [[Combination Hemotherapy And Mortality Prevention (Champ) Study]] | | [[Combination Hemotherapy And Mortality Prevention (Champ) Study]] | ||
|- | |- | ||
| CHAMP | | [[CHAMP]] | ||
| [[Children's Hiv And Aids Model Program]] | | [[Children's Hiv And Aids Model Program]] | ||
|- | |- | ||
| CHAMPIONS | | [[CHAMPIONS]] | ||
| [[Controlled High-Risk Subjects Avonex Ms Prevention In Ongoing Neurologic Surveillance]] | | [[Controlled High-Risk Subjects Avonex Ms Prevention In Ongoing Neurologic Surveillance]] | ||
|- | |- | ||
| CHAMPS | | [[CHAMPS]] | ||
| [[Controlled High-Risk Subjects Avonex Ms Prevention Study]] | | [[Controlled High-Risk Subjects Avonex Ms Prevention Study]] | ||
|- | |- | ||
| CHAOS | | [[CHAOS]] | ||
| [[Cambridge Heart Antioxidant Study]] | | [[Cambridge Heart Antioxidant Study]] | ||
|- | |- | ||
| CHARISMA | | [[CHARISMA]] | ||
| [[Clopidogrel For High Atherothrombotic Risk, Ischemic Stabilization, Management, And Avoidance]] | | [[Clopidogrel For High Atherothrombotic Risk, Ischemic Stabilization, Management, And Avoidance]] | ||
|- | |- | ||
| CHARM | | [[CHARM]] | ||
| [[Candesartan Cilexitil (Atacand) In Heart Failure Assessment Of Reduction Mortality And Morbidity]] | | [[Candesartan Cilexitil (Atacand) In Heart Failure Assessment Of Reduction Mortality And Morbidity]] | ||
|- | |- | ||
| CHARM Added Trial | | [[CHARM Added Trial]] | ||
| [[Candesartan In Heart Failure—Added Trial]] | | [[Candesartan In Heart Failure—Added Trial]] | ||
|- | |- | ||
| CHARM Alternative Trial | | [[CHARM Alternative Trial]] | ||
| [[Candesartan In Heart Failure—Alternative Trial]] | | [[Candesartan In Heart Failure—Alternative Trial]] | ||
|- | |- | ||
| CHARM Overall Programme Results | | [[CHARM Overall Programme Results]] | ||
| [[Candesartan In Heart Failure—Assessment Of Reduction In Mortality And Morbidity]] | | [[Candesartan In Heart Failure—Assessment Of Reduction In Mortality And Morbidity]] | ||
|- | |- | ||
| CHARM Preserved Trial | | [[CHARM Preserved Trial]] | ||
| [[Candesartan In Heart Failure—Preserved Trial]] | | [[Candesartan In Heart Failure—Preserved Trial]] | ||
|- | |- | ||
| CHEESE | | [[CHEESE]] | ||
| [[Comparative Trial Of Hiv-Infected Patients Evaluating Efficacy And Safety Of Saquinavir-Enhanced Oral Formulation And Indinavir Given As Part Of A Triple Drug Therapy ]] | | [[Comparative Trial Of Hiv-Infected Patients Evaluating Efficacy And Safety Of Saquinavir-Enhanced Oral Formulation And Indinavir Given As Part Of A Triple Drug Therapy ]] | ||
|- | |- | ||
| CHF STAT | | [[CHF STAT]] | ||
| [[Amiodarone In Patients With Congestive Heart Failue And Asymptomatic Ventricular Arrhythmia]] | | [[Amiodarone In Patients With Congestive Heart Failue And Asymptomatic Ventricular Arrhythmia]] | ||
|- | |- | ||
| CHF-STAT | | [[CHF-STAT]] | ||
| [[Congestive Heart Failure Survival Trial Of Antiarrhythmic Therapy]] | | [[Congestive Heart Failure Survival Trial Of Antiarrhythmic Therapy]] | ||
|- | |- | ||
| CHICAGO | | [[CHICAGO]] | ||
| [[Carotid Intima-Media Thickness In Atherosclerosis Using Pioglitazone]] | | [[Carotid Intima-Media Thickness In Atherosclerosis Using Pioglitazone]] | ||
|- | |- | ||
| CHRISTMAS | | [[CHRISTMAS]] | ||
| [[Carvedilol Hibernating Reversible Ischaemia Trial]] | | [[Carvedilol Hibernating Reversible Ischaemia Trial]] | ||
|- | |- | ||
| CHRISTMAS | | [[CHRISTMAS]] | ||
| [[Carvedilol Hibernation Reversible Ischemia Trial Marker Of Success]] | | [[Carvedilol Hibernation Reversible Ischemia Trial Marker Of Success]] | ||
|- | |- | ||
| CHS | | [[CHS]] | ||
| [[Cardiovascular Health Study]] | | [[Cardiovascular Health Study]] | ||
|- | |- | ||
| CHS | | [[CHS]] | ||
| [[Cardiovascular Health StudyCharleston Heart StudyCommunity Health StudyCongenital Heart Surgeons Society StudyCoronary Heart Study]] | | [[Cardiovascular Health StudyCharleston Heart StudyCommunity Health StudyCongenital Heart Surgeons Society StudyCoronary Heart Study]] | ||
|- | |- | ||
| CIAO | | [[CIAO]] | ||
| [[Coronary Interventions Antiplatelet-Based Only]] | | [[Coronary Interventions Antiplatelet-Based Only]] | ||
|- | |- | ||
| [[CIBIS]] | |||
| [[ | |||
| [[Cardiac Insufficiency Bisoprolol Study]] | | [[Cardiac Insufficiency Bisoprolol Study]] | ||
|- | |- | ||
| CIBIS II | | [[CIBIS II]] | ||
| [[The Cardiac Insufficiency Bisoprolol Study II]] | | [[The Cardiac Insufficiency Bisoprolol Study II]] | ||
|- | |- | ||
| CIBIS III | | [[CIBIS III]] | ||
| [[Canadian Implantable Defibrillator Study]] | | [[Canadian Implantable Defibrillator Study]] | ||
|- | |- | ||
| CIDS | | [[CIDS]] | ||
| [[Canadian Implantable Defibrillator Study]] | | [[Canadian Implantable Defibrillator Study]] | ||
|- | |- | ||
| CIGTS | | [[CIGTS]] | ||
| [[Collaborative Initial Glaucoma Treatment Study]] | | [[Collaborative Initial Glaucoma Treatment Study]] | ||
|- | |- | ||
| CLARIDI | | [[CLARIDI]] | ||
| [[Cholesterol Lowering And Arrhythmias Recurrences After Internal Defibrillator Implantation]] | | [[Cholesterol Lowering And Arrhythmias Recurrences After Internal Defibrillator Implantation]] | ||
|- | |- | ||
| CLARITY-TIMI 28 | | [[CLARITY-TIMI 28]] | ||
| [[Clopidogrel As Adjunctive Reperfusion Therapy]] | | [[Clopidogrel As Adjunctive Reperfusion Therapy]] | ||
|- | |- | ||
| CLAS I AND II | | [[CLAS I AND II]] | ||
| [[Cholesterol Lowering Atherosclerosis Study (I And II)]] | | [[Cholesterol Lowering Atherosclerosis Study (I And II)]] | ||
|- | |- | ||
| CLASS | | [[CLASS]] | ||
| [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | | [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | ||
|- | |- | ||
| CLASSICS | | [[CLASSICS]] | ||
| [[The Clopidogrel Aspirin Stent International Cooperative Study (Classics)]] | | [[The Clopidogrel Aspirin Stent International Cooperative Study (Classics)]] | ||
|- | |- | ||
| CLASSICS | | [[CLASSICS]] | ||
| [[Clopidogrel (Plavix) Aspirin Stent International Cooperative Study]] | | [[Clopidogrel (Plavix) Aspirin Stent International Cooperative Study]] | ||
|- | |- | ||
| CLASS-IHT | | [[CLASS-IHT]] | ||
| [[Clomethiazole Acute Stroke Study In Ischemic, Hemorrhagic, And Tpa Treated Stroke]] | | [[Clomethiazole Acute Stroke Study In Ischemic, Hemorrhagic, And Tpa Treated Stroke]] | ||
|- | |- | ||
| CLEAR PLATELETS | | [[CLEAR PLATELETS]] | ||
| [[Clopidogrel Loading With Eptifibatide To Arrest The Reactivity Of Platelets Study]] | | [[Clopidogrel Loading With Eptifibatide To Arrest The Reactivity Of Platelets Study]] | ||
|- | |- | ||
| CLEAR PLATELETS-2 | | [[CLEAR PLATELETS-2]] | ||
| [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets]] | | [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets]] | ||
|- | |- | ||
| CLEERE | | [[CLEERE]] | ||
| [[Collaborative Longitudinal Evaluation Of Ethnicity And Refractive Error]] | | [[Collaborative Longitudinal Evaluation Of Ethnicity And Refractive Error]] | ||
|- | |- | ||
| COACH | | [[COACH]] | ||
| [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | | [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | ||
|- | |- | ||
| COAST | | [[COAST]] | ||
| [[Heparin-Coated Stents In Small Coronary Arteries]] | | [[Heparin-Coated Stents In Small Coronary Arteries]] | ||
|- | |- | ||
| COAST | | [[COAST]] | ||
| [[Heparin-Coated Stents In Small Coronary Arteries]] | | [[Heparin-Coated Stents In Small Coronary Arteries]] | ||
|- | |- | ||
| COBALT | | [[COBALT]] | ||
| [[Continuous Infusion Versus Double-Bolus Administration Of Alteplase]] | | [[Continuous Infusion Versus Double-Bolus Administration Of Alteplase]] | ||
|- | |- | ||
| COCAD | | [[COCAD]] | ||
| [[Cognitive Outcomes In Coronary Artery Disease]] | | [[Cognitive Outcomes In Coronary Artery Disease]] | ||
|- | |- | ||
| COLA | | [[COLA]] | ||
| [[Carvedilol Open Label Assessment]] | | [[Carvedilol Open Label Assessment]] | ||
|- | |- | ||
| COLUMBUS | | [[COLUMBUS]] | ||
| [[Low Molecular Weight Heparin In The Treatment Of Patients With Venous Thromboembolism]] | | [[Low Molecular Weight Heparin In The Treatment Of Patients With Venous Thromboembolism]] | ||
|- | |- | ||
| COMBINE | | [[COMBINE]] | ||
| [[Combining Medications And Behavorial Interventions ]] | | [[Combining Medications And Behavorial Interventions ]] | ||
|- | |- | ||
| COMET | | [[COMET]] | ||
| [[Carvedilol Or Metoprolol European Trial]] | | [[Carvedilol Or Metoprolol European Trial]] | ||
|- | |- | ||
| COMET | | [[COMET]] | ||
| [[Carvedilol Or Metoprolol European Trial]] | | [[Carvedilol Or Metoprolol European Trial]] | ||
|- | |- | ||
| COMMA | | [[COMMA]] | ||
| [[Compliment Inhibition In Myocardial Infarction Treated With Percutaneous Transluminal Coronary Angioplasty (Evaluation Of Iv Dosing Regimens Of H5G1.1-Scfv) ]] | | [[Compliment Inhibition In Myocardial Infarction Treated With Percutaneous Transluminal Coronary Angioplasty (Evaluation Of Iv Dosing Regimens Of H5G1.1-Scfv) ]] | ||
|- | |- | ||
| COMMIT/CCS-2 – Clopidogrel | | [[COMMIT/CCS-2 – Clopidogrel]] | ||
| [[Randomized, Placebo-Controlled Trial Of Adding Clopidogrel To Aspirin In 46,000 Acute Myocardial Infarction Patients]] | | [[Randomized, Placebo-Controlled Trial Of Adding Clopidogrel To Aspirin In 46,000 Acute Myocardial Infarction Patients]] | ||
|- | |- | ||
| COMMIT/CCS-2 – Metoprolol | | [[COMMIT/CCS-2 – Metoprolol]] | ||
| [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | | [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | ||
|- | |- | ||
| COMPANION | | [[COMPANION]] | ||
| [[Comparison Of Medical Therapy, Pacing And Defibrillation In Heart Failure]] | | [[Comparison Of Medical Therapy, Pacing And Defibrillation In Heart Failure]] | ||
|- | |- | ||
| COMPANION | | [[COMPANION]] | ||
| [[Comparison Of Medical Therapy, Pacing And Defibrillation In Chronic Heart Failure]] | | [[Comparison Of Medical Therapy, Pacing And Defibrillation In Chronic Heart Failure]] | ||
|- | |- | ||
| Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenosis | | [[Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenosis]] | ||
| [[Randomized Clinical Trial Investigators. Randomized Comparison Of Gr-II Stent And Palmaz-Schatz Stent For Elective Treatment Of Coronary Stenosis]] | | [[Randomized Clinical Trial Investigators. Randomized Comparison Of Gr-II Stent And Palmaz-Schatz Stent For Elective Treatment Of Coronary Stenosis]] | ||
|- | |- | ||
| Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus Arteriosus | | [[Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus Arteriosus]] | ||
| [[A Comparison Of Ibuprofen And Indomethacin For Closure Of Patent Ductus Arteriosus]] | | [[A Comparison Of Ibuprofen And Indomethacin For Closure Of Patent Ductus Arteriosus]] | ||
|- | |- | ||
| COMPASS | | [[COMPASS]] | ||
| [[Comparison Trial Of Saruplase And Streptokinase]] | | [[Comparison Trial Of Saruplase And Streptokinase]] | ||
|- | |- | ||
| COMPASS-HF | | [[COMPASS-HF]] | ||
| [[Chronicle Offers Management To Patients With Advanced Signs And Symptoms Of Heart Failure]] | | [[Chronicle Offers Management To Patients With Advanced Signs And Symptoms Of Heart Failure]] | ||
|- | |- | ||
| COMPLY | | [[COMPLY]] | ||
| [[Compliment Inhibition In Myocardial Infarction Treated With Thrombolytics [Evaluation Of Iv Dosing Regimens Of H5G1.1-Scfv] Sponsors]] | | [[Compliment Inhibition In Myocardial Infarction Treated With Thrombolytics [Evaluation Of Iv Dosing Regimens Of H5G1.1-Scfv] Sponsors]] | ||
|- | |- | ||
| COMS | | [[COMS]] | ||
| [[Collaborative Ocular Melanoma Study]] | | [[Collaborative Ocular Melanoma Study]] | ||
|- | |- | ||
| CONSENSUS | | [[CONSENSUS]] | ||
| [[The Effects Of Enalapril On Mortality In Severe Congestive Heart Failure]] | | [[The Effects Of Enalapril On Mortality In Severe Congestive Heart Failure]] | ||
|- | |- | ||
| CONSENSUS II | | [[CONSENSUS II]] | ||
| [[The Effects Of The Early Administration Of Enalapril On Mortality In Patients With Acute Myocardial Infarction: Results Of The Cooperative New Scandin]] | | [[The Effects Of The Early Administration Of Enalapril On Mortality In Patients With Acute Myocardial Infarction: Results Of The Cooperative New Scandin]] | ||
|- | |- | ||
| CONVERTIBLE | | [[CONVERTIBLE]] | ||
| [[Conventional Stenting Versus Direct Stenting In (Un)Stable Angina Pectoris]] | | [[Conventional Stenting Versus Direct Stenting In (Un)Stable Angina Pectoris]] | ||
|- | |- | ||
| CONVINCE | | [[CONVINCE]] | ||
| [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | | [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | ||
|- | |- | ||
| CONVINCE | | [[CONVINCE]] | ||
| [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints]] | | [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints]] | ||
|- | |- | ||
| COOL | | [[COOL]] | ||
| [[Cardiovascular Thrombolytic To Open Occluded Lines]] | | [[Cardiovascular Thrombolytic To Open Occluded Lines]] | ||
|- | |- | ||
| COOL AID | | [[COOL AID]] | ||
| [[Cooling For Acute Ischemic Brain Damage]] | | [[Cooling For Acute Ischemic Brain Damage]] | ||
|- | |- | ||
| COOL MI | | [[COOL MI]] | ||
| [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | | [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | ||
|- | |- | ||
| COOL-MI | | [[COOL-MI]] | ||
| [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | | [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | ||
|- | |- | ||
| COOLRCN | | [[COOLRCN]] | ||
| [[Cooling To Prevent Radiocontrast Nephropathy]] | | [[Cooling To Prevent Radiocontrast Nephropathy]] | ||
|- | |- | ||
| COPERNICUS | | [[COPERNICUS]] | ||
| [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | | [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | ||
|- | |- | ||
| COPERNICUS | | [[COPERNICUS]] | ||
| [[Carvedilol (Coreg) Prospective Randomized Cumulative Survival]] | | [[Carvedilol (Coreg) Prospective Randomized Cumulative Survival]] | ||
|- | |- | ||
| COPPA | | [[COPPA]] | ||
| [[Clinical Outcomes From The Prevention Of Postoperative Arrhythmia]] | | [[Clinical Outcomes From The Prevention Of Postoperative Arrhythmia]] | ||
|- | |- | ||
| CORE | | [[CORE]] | ||
| [[International Variation In Invasive Procedures And Outcomes In Acute Myocardial Infarction]] | | [[International Variation In Invasive Procedures And Outcomes In Acute Myocardial Infarction]] | ||
|- | |- | ||
| CORE | | [[CORE]] | ||
| [[Continuing Outcomes Relevant To Evista]] | | [[Continuing Outcomes Relevant To Evista]] | ||
|- | |- | ||
| CORONA | | [[CORONA]] | ||
| [[Controlled Rosuvastatin Multinational Trial In Heart Failure]] | | [[Controlled Rosuvastatin Multinational Trial In Heart Failure]] | ||
|- | |- | ||
| CORSICA | | [[CORSICA]] | ||
| [[Chronic Occlusion Revascularization With Stent Implantation Versus Coronary Angioplasty]] | | [[Chronic Occlusion Revascularization With Stent Implantation Versus Coronary Angioplasty]] | ||
|- | |- | ||
| COSS | | [[COSS]] | ||
| [[Carotid Occlusion Surgery Study]] | | [[Carotid Occlusion Surgery Study]] | ||
|- | |- | ||
| COURAGE | | [[COURAGE]] | ||
| [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | | [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | ||
|- | |- | ||
| COURAGE | | [[COURAGE]] | ||
| [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation]] | | [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation]] | ||
|- | |- | ||
| COURT | | [[COURT]] | ||
| [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | | [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | ||
|- | |- | ||
| COURT | | [[COURT]] | ||
| [[A Randomized Trial Of Contrast Media Utilization In High Risk Ptca]] | | [[A Randomized Trial Of Contrast Media Utilization In High Risk Ptca]] | ||
|- | |- | ||
| C-PORT | | [[C-PORT]] | ||
| [[Atlantic Cardiovascular Patient Outcomes Research Team Trial]] | | [[Atlantic Cardiovascular Patient Outcomes Research Team Trial]] | ||
|- | |- | ||
| CPVA for Chronic Atrial Fibrillation | | [[CPVA for Chronic Atrial Fibrillation]] | ||
| [[Circumferential Pulmonary Vein Ablation For Chronic Atrial Fibrillation]] | | [[Circumferential Pulmonary Vein Ablation For Chronic Atrial Fibrillation]] | ||
|- | |- | ||
| CQI in CABG | | [[CQI in CABG]] | ||
| [[Continuous Quality Improvement In Coranary Artery Bypass Graft]] | | [[Continuous Quality Improvement In Coranary Artery Bypass Graft]] | ||
|- | |- | ||
| CRASH | | [[CRASH]] | ||
| [[Corticosteroid Randomization After Significant Head Injury]] | | [[Corticosteroid Randomization After Significant Head Injury]] | ||
|- | |- | ||
| CREATE | | [[CREATE]] | ||
| [[Canadian Cardiac Randomized Evaluation Of Antidepressant And Psychotherapy Efficacy]] | | [[Canadian Cardiac Randomized Evaluation Of Antidepressant And Psychotherapy Efficacy]] | ||
|- | |- | ||
| CREATE ELCA - Reviparin | | [[CREATE ELCA - Reviparin]] | ||
| [[Low Molecular Weight Heparin (Reviparin) In Preventing Mortality, Reinfarction, And Strokes In Over 15,500 Patients With St Elevation Acute Myocardial Infarction]] | | [[Low Molecular Weight Heparin (Reviparin) In Preventing Mortality, Reinfarction, And Strokes In Over 15,500 Patients With St Elevation Acute Myocardial Infarction]] | ||
|- | |- | ||
| CREATE-ECLA - GIK | | [[CREATE-ECLA - GIK]] | ||
| [[Impact Of Glucose-Insulin-Potassium On Mortality And Morbidity In Over 20,000 Patients With Acute Myocardial Infarction: The Create-Ecla International Trial]] | | [[Impact Of Glucose-Insulin-Potassium On Mortality And Morbidity In Over 20,000 Patients With Acute Myocardial Infarction: The Create-Ecla International Trial]] | ||
|- | |- | ||
| CREDO | | [[CREDO]] | ||
| [[Clopidogrel For Reduction Of Events During Observation]] | | [[Clopidogrel For Reduction Of Events During Observation]] | ||
|- | |- | ||
| [[CREST]] | |||
| [[ | |||
| [[Cilostazol For Restenosis]] | | [[Cilostazol For Restenosis]] | ||
|- | |- | ||
| CREST | | [[CREST]] | ||
| [[Carotid Revascularization Endarterectomy Vs Stenting Trial]] | | [[Carotid Revascularization Endarterectomy Vs Stenting Trial]] | ||
|- | |- | ||
| CRIS | | [[CRIS]] | ||
| [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | | [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | ||
|- | |- | ||
| CRUISE | | [[CRUISE]] | ||
| [[Final Results Of The Can Routine Ultrasound Influence Stent Expansion (Cruise) Study]] | | [[Final Results Of The Can Routine Ultrasound Influence Stent Expansion (Cruise) Study]] | ||
|- | |- | ||
| CRUISE | | [[CRUISE]] | ||
| [[Can Routine Ultrasound Influence Stent Expansion]] | | [[Can Routine Ultrasound Influence Stent Expansion]] | ||
|- | |- | ||
| C-SIRIUS | | [[C-SIRIUS]] | ||
| [[Canadian Sirolimus-Eluting Stent In Coronary Lesions]] | | [[Canadian Sirolimus-Eluting Stent In Coronary Lesions]] | ||
|- | |- | ||
| CSSS | | [[CSSS]] | ||
| [[China Salt Substitute Study]] | | [[China Salt Substitute Study]] | ||
|- | |- | ||
| CTAF | | [[CTAF]] | ||
| [[Canadian Trial Of Atrial Fibrillation]] | | [[Canadian Trial Of Atrial Fibrillation]] | ||
|- | |- | ||
| CTOPP | | [[CTOPP]] | ||
| [[Canadian Trial Of Physiologic Pacing]] | | [[Canadian Trial Of Physiologic Pacing]] | ||
|- | |- | ||
| CUBA | | [[CUBA]] | ||
| [[Cutting Balloon Versus Conventional Angioplasty Study]] | | [[Cutting Balloon Versus Conventional Angioplasty Study]] | ||
|- | |- | ||
| CURE | | [[CURE]] | ||
| [[The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial Investigators: Effects Of Clopidogrel In Addition To Aspirin In Patients With Acute Coronary Syndromes Without St-Segment Elevation]] | | [[The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial Investigators: Effects Of Clopidogrel In Addition To Aspirin In Patients With Acute Coronary Syndromes Without St-Segment Elevation]] | ||
|- | |- | ||
| CURE | | [[CURE]] | ||
| [[Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events]] | | [[Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events]] | ||
|- | |- | ||
| DAIS | | [[DAIS]] | ||
| [[Diabetes Atherosclerosis Intervention Study]] | | [[Diabetes Atherosclerosis Intervention Study]] | ||
|- | |- | ||
| [[DAISY]] | |||
| [[ | |||
| [[Diabetes Autoimmunity Study In The Young]] | | [[Diabetes Autoimmunity Study In The Young]] | ||
|- | |- | ||
| DANAMI | | [[DANAMI]] | ||
| [[Danish Myocardial Infarction Trial]] | | [[Danish Myocardial Infarction Trial]] | ||
|- | |- | ||
| DANAMI-2 | | [[DANAMI-2]] | ||
| [[Danish Trial In Acute Myocardial Infarction-2]] | | [[Danish Trial In Acute Myocardial Infarction-2]] | ||
|- | |- | ||
| DANTE | | [[DANTE]] | ||
| [[Diabetes Abciximab Stent Evaluation]] | | [[Diabetes Abciximab Stent Evaluation]] | ||
|- | |- | ||
| DAPPAF | | [[DAPPAF]] | ||
| [[Dual Site Atrial Pacing To Prevent Atrial Fibrillation]] | | [[Dual Site Atrial Pacing To Prevent Atrial Fibrillation]] | ||
|- | |- | ||
| DART | | [[DART]] | ||
| [[Dilation Versus Ablation Revascularization Trial]] | | [[Dilation Versus Ablation Revascularization Trial]] | ||
|- | |- | ||
| DASH | | [[DASH]] | ||
| [[Dietary Approaches To Stop Hypertension]] | | [[Dietary Approaches To Stop Hypertension]] | ||
|- | |- | ||
| DATATOP | | [[DATATOP]] | ||
| [[Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism]] | | [[Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism]] | ||
|- | |- | ||
| DAVID | | [[DAVID]] | ||
| [[Dual Chamber And Vvi Implantable Defibrillator (David) Trial]] | | [[Dual Chamber And Vvi Implantable Defibrillator (David) Trial]] | ||
|- | |- | ||
| DAVID | | [[DAVID]] | ||
| [[Dual-Chamber And Vvi Implantable Defibrillator]] | | [[Dual-Chamber And Vvi Implantable Defibrillator]] | ||
|- | |- | ||
| DAVID – (Picotamide vs. Aspirin) | | [[DAVID – (Picotamide vs. Aspirin)]] | ||
| [[Drug Evaluation In Atherosclerotic Vascular Disease In Diabetics]] | | [[Drug Evaluation In Atherosclerotic Vascular Disease In Diabetics]] | ||
|- | |- | ||
| DAVID II | | [[DAVID II]] | ||
| [[Dual Chamber And Vvi Implantable Defibrillator II]] | | [[Dual Chamber And Vvi Implantable Defibrillator II]] | ||
|- | |- | ||
| DAVIT II | | [[DAVIT II]] | ||
| [[Danish Study Group On Verapamil In Mi]] | | [[Danish Study Group On Verapamil In Mi]] | ||
|- | |- | ||
| DCCT | | [[DCCT]] | ||
| [[Diabetes Control And Complications Trial]] | | [[Diabetes Control And Complications Trial]] | ||
|- | |- | ||
| DEAR-MI | | [[DEAR-MI]] | ||
| [[Dethrombosis To Enhance Acute Reperfusion In Myocardial Infarction]] | | [[Dethrombosis To Enhance Acute Reperfusion In Myocardial Infarction]] | ||
|- | |- | ||
| DEBATE | | [[DEBATE]] | ||
| [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | | [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | ||
|- | |- | ||
| DEBATE | | [[DEBATE]] | ||
| [[Doppler Endpoints Balloon Angioplasty Trial Europe ]] | | [[Doppler Endpoints Balloon Angioplasty Trial Europe ]] | ||
|- | |- | ||
| DEBATE II | | [[DEBATE II]] | ||
| [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | | [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | ||
|- | |- | ||
| DEBUT | | [[DEBUT]] | ||
| [[Defibrillator Versus Beta-Blockers For Unexplained Death In Thailand]] | | [[Defibrillator Versus Beta-Blockers For Unexplained Death In Thailand]] | ||
|- | |- | ||
| DECLARE-DIABETES | | [[DECLARE-DIABETES]] | ||
| [[Drug-Eluting Stenting Followed By Cilostazol Treatment Reduces Late Restenosis In Patients With Diabetes Mellitus]] | | [[Drug-Eluting Stenting Followed By Cilostazol Treatment Reduces Late Restenosis In Patients With Diabetes Mellitus]] | ||
|- | |- | ||
| DECOPI | | [[DECOPI]] | ||
| [[Randomized Trial Of Occluded Artery Angioplasty After Acute Myocardial Infarction]] | | [[Randomized Trial Of Occluded Artery Angioplasty After Acute Myocardial Infarction]] | ||
|- | |- | ||
| DECOPI | | [[DECOPI]] | ||
| [[La Desobstruction Coronaire En Post-Infarctus ]] | | [[La Desobstruction Coronaire En Post-Infarctus ]] | ||
|- | |- | ||
| DECREASE III | | [[DECREASE III]] | ||
| [[Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo III]] | | [[Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo III]] | ||
|- | |- | ||
| DECREASE-V | | [[DECREASE-V]] | ||
| [[Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-V]] | | [[Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-V]] | ||
|- | |- | ||
| DEDICATION: Distal Protection Study | | [[DEDICATION: Distal Protection Study]] | ||
| [[Drug Elution And Distal Protection In St-Elevation Myocardial Infarction]] | | [[Drug Elution And Distal Protection In St-Elevation Myocardial Infarction]] | ||
|- | |- | ||
| DEDICATION: Stent Study | | [[DEDICATION: Stent Study]] | ||
| [[Drug Elution And Distal Protection In Acute Myocardial Infarction]] | | [[Drug Elution And Distal Protection In Acute Myocardial Infarction]] | ||
|- | |- | ||
| DEFER | | [[DEFER]] | ||
| [[Deferral Versus Performance Of Ptca In Patients Without Documented Ischemia]] | | [[Deferral Versus Performance Of Ptca In Patients Without Documented Ischemia]] | ||
|- | |- | ||
| [[DEFINITE]] | |||
| [[ | |||
| [[Defibrillators In Nonischemic Cardiomyopathy Treatment Evaluation]] | | [[Defibrillators In Nonischemic Cardiomyopathy Treatment Evaluation]] | ||
|- | |- | ||
| DEFUSE | | [[DEFUSE]] | ||
| [[Diffusion-Weighted Imaging Evaluation For Understanding Stroke Evaluation ]] | | [[Diffusion-Weighted Imaging Evaluation For Understanding Stroke Evaluation ]] | ||
|- | |- | ||
| DELTA MI | | [[DELTA MI]] | ||
| [[Direct Inhibition Of Δ-Protein Kinase C Enzyme To Limit Total Infarct Size In Acute Mi]] | | [[Direct Inhibition Of Δ-Protein Kinase C Enzyme To Limit Total Infarct Size In Acute Mi]] | ||
|- | |- | ||
| DES-DIABETES | | [[DES-DIABETES]] | ||
| [[A Randomized Comparison Of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation In Patients With Diabetes Mellitus]] | | [[A Randomized Comparison Of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation In Patients With Diabetes Mellitus]] | ||
|- | |- | ||
| DESTINI-CFR | | [[DESTINI-CFR]] | ||
| [[Doppler Endpoints Stenting International Investigation - Coronary Flow Reserve ]] | | [[Doppler Endpoints Stenting International Investigation - Coronary Flow Reserve ]] | ||
|- | |- | ||
| DETAIL | | [[DETAIL]] | ||
| [[Diabetics Exposed To Telmisartan And Enalapril]] | | [[Diabetics Exposed To Telmisartan And Enalapril]] | ||
|- | |- | ||
| DIABETES | | [[DIABETES]] | ||
| [[Diabetes And Sirolimus-Eluting Stent Trial]] | | [[Diabetes And Sirolimus-Eluting Stent Trial]] | ||
|- | |- | ||
| DIABETES | | [[DIABETES]] | ||
| [[A Prospective, Randomized, Controlled Trial Of The Polymer-Based, Sirolimus-Eluting Stent Versus A Bare Metal Stent In Patients With Diabetes Mellitus]] | | [[A Prospective, Randomized, Controlled Trial Of The Polymer-Based, Sirolimus-Eluting Stent Versus A Bare Metal Stent In Patients With Diabetes Mellitus]] | ||
|- | |- | ||
| DIACOR | | [[DIACOR]] | ||
| [[Diabetes And Combined Lipid Therapy Regimen]] | | [[Diabetes And Combined Lipid Therapy Regimen]] | ||
|- | |- | ||
| DIAD | | [[DIAD]] | ||
| [[Detection Of Ischemia In Asymptomatic Diabetics]] | | [[Detection Of Ischemia In Asymptomatic Diabetics]] | ||
|- | |- | ||
| DIADS | | [[DIADS]] | ||
| [[Depression In Alzheimer Disease Study]] | | [[Depression In Alzheimer Disease Study]] | ||
|- | |- | ||
| DIAGNOSIS | | [[DIAGNOSIS]] | ||
| [[Diffusion-Weighted Imaging Assessment Of The Genuine Need For Other Studies In Ischemic Stroke]] | | [[Diffusion-Weighted Imaging Assessment Of The Genuine Need For Other Studies In Ischemic Stroke]] | ||
|- | |- | ||
| DIAL | | [[DIAL]] | ||
| [[Randomized Trial Of Telephone Intervention In Chronic Heart Failure]] | | [[Randomized Trial Of Telephone Intervention In Chronic Heart Failure]] | ||
|- | |- | ||
| DIAMOND | | [[DIAMOND]] | ||
| [[Danish Investigations Of Arrhythmia And Mortality On Dofetilide]] | | [[Danish Investigations Of Arrhythmia And Mortality On Dofetilide]] | ||
|- | |- | ||
| DIAMOND | | [[DIAMOND]] | ||
| [[Distensibility Improvement With Alt-711 Remodeling In Diastolic Heart Failure Sponsor]] | | [[Distensibility Improvement With Alt-711 Remodeling In Diastolic Heart Failure Sponsor]] | ||
|- | |- | ||
| DIAMOND CHF | | [[DIAMOND CHF]] | ||
| [[Danish Investigators Of Arrhythmia And Mortality On Dofetilde Congestive Heart Failure ]] | | [[Danish Investigators Of Arrhythmia And Mortality On Dofetilde Congestive Heart Failure ]] | ||
|- | |- | ||
| DIDI | | [[DIDI]] | ||
| [[Diltiazem In Dilated Cardiomyopathy]] | | [[Diltiazem In Dilated Cardiomyopathy]] | ||
|- | |- | ||
| DIG | | [[DIG]] | ||
| [[Digoxin Investigation Group]] | | [[Digoxin Investigation Group]] | ||
|- | |- | ||
| DIG Enalapril | | [[DIG Enalapril]] | ||
| [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | | [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | ||
|- | |- | ||
| DIGAMI | | [[DIGAMI]] | ||
| [[Diabetic Insulin-Glucose Infusion In Acute Mi]] | | [[Diabetic Insulin-Glucose Infusion In Acute Mi]] | ||
|- | |- | ||
| DIGAMI | | [[DIGAMI]] | ||
| [[Diabetes Mellitus Insulin-Glucose Infusion In Acute Myocardial Infarction]] | | [[Diabetes Mellitus Insulin-Glucose Infusion In Acute Myocardial Infarction]] | ||
|- | |- | ||
| DIMT | | [[DIMT]] | ||
| [[Double-Blind Placebo-Controlled Study Of Ibopamine And Digoxin In Patients With Mild To Moderate Heart Failure: Results Of The Dutch Ibopamine Multic]] | | [[Double-Blind Placebo-Controlled Study Of Ibopamine And Digoxin In Patients With Mild To Moderate Heart Failure: Results Of The Dutch Ibopamine Multic]] | ||
|- | |- | ||
| [[DINAMIT]] | |||
| [[ | |||
| [[Defibrillation In Acute Myocardial Infarction Trial]] | | [[Defibrillation In Acute Myocardial Infarction Trial]] | ||
|- | |- | ||
| DIPOM | | [[DIPOM]] | ||
| [[Diabetic Postoperative Mortality And Morbidity Trial]] | | [[Diabetic Postoperative Mortality And Morbidity Trial]] | ||
|- | |- | ||
| DIRECT | | [[DIRECT]] | ||
| [[Direct Stenting Using The Sirolimus-Eluting Stent]] | | [[Direct Stenting Using The Sirolimus-Eluting Stent]] | ||
|- | |- | ||
| DIRECT | | [[DIRECT]] | ||
| [[Direct Myocardial Revascularization In Regeneration Of Endocardial Channels Trial]] | | [[Direct Myocardial Revascularization In Regeneration Of Endocardial Channels Trial]] | ||
|- | |- | ||
| DIRECT | | [[DIRECT]] | ||
| [[Diabetic Retinopathy Candesartan Trial Candesartan Cilexetil (Atacand)]] | | [[Diabetic Retinopathy Candesartan Trial Candesartan Cilexetil (Atacand)]] | ||
|- | |- | ||
| DIRECTOR | | [[DIRECTOR]] | ||
| [[Direct Stenting Study With Orbus R Stent]] | | [[Direct Stenting Study With Orbus R Stent]] | ||
|- | |- | ||
| DISC | | [[DISC]] | ||
| [[Disability In Strategies For Care]] | | [[Disability In Strategies For Care]] | ||
|- | |- | ||
| DISCO | | [[DISCO]] | ||
| [[Direct Coronary Stenting Versus Stenting With Balloon Predilation: Immediate And Follow-Up Results]] | | [[Direct Coronary Stenting Versus Stenting With Balloon Predilation: Immediate And Follow-Up Results]] | ||
|- | |- | ||
| DISTINCT | | [[DISTINCT]] | ||
| [[Biodivysio Stent In Controlled Trial]] | | [[Biodivysio Stent In Controlled Trial]] | ||
|- | |- | ||
| DMIST | | [[DMIST]] | ||
| [[Digital Mammographic Imaging Screening Trial]] | | [[Digital Mammographic Imaging Screening Trial]] | ||
|- | |- | ||
| DPP | | [[DPP]] | ||
| [[Diabetes Prevention Program Trial]] | | [[Diabetes Prevention Program Trial]] | ||
|- | |- | ||
| DPT-1 | | [[DPT-1]] | ||
| [[Diabetes Prevention Trial - Type 1 ]] | | [[Diabetes Prevention Trial - Type 1 ]] | ||
|- | |- | ||
| DREAM | | [[DREAM]] | ||
| [[Diabetes Reduction Approaches With Ramipril And Rosiglitazone Medications]] | | [[Diabetes Reduction Approaches With Ramipril And Rosiglitazone Medications]] | ||
|- | |- | ||
| DREAM - Ramipril | | [[DREAM - Ramipril]] | ||
| [[Diabetes Reduction Assessment With Ramipril And Rosiglitazone Medication]] | | [[Diabetes Reduction Assessment With Ramipril And Rosiglitazone Medication]] | ||
|- | |- | ||
| DREAM - Rosiglitazone | | [[DREAM - Rosiglitazone]] | ||
| [[Diabetes Reduction Assessment With Ramipril And Rosiglitazone Medication]] | | [[Diabetes Reduction Assessment With Ramipril And Rosiglitazone Medication]] | ||
|- | |- | ||
| DUCCS-1 | | [[DUCCS-1]] | ||
| [[Duke University Clinical Cardiology Study - 1]] | | [[Duke University Clinical Cardiology Study - 1]] | ||
|- | |- | ||
| DUCCS-2 | | [[DUCCS-2]] | ||
| [[Duke University Clinical Cardiology Study - 2]] | | [[Duke University Clinical Cardiology Study - 2]] | ||
|- | |- | ||
| DYSBOT | | [[DYSBOT]] | ||
| [[Dysport And Botox Study ]] | | [[Dysport And Botox Study ]] | ||
|- | |- | ||
| EAFT | | [[EAFT]] | ||
| [[European Atrial Fibrillation Trial]] | | [[European Atrial Fibrillation Trial]] | ||
|- | |- | ||
| EAGAR | | [[EAGAR]] | ||
| [[Estrogen And Graft Atherosclerosis Research Trial]] | | [[Estrogen And Graft Atherosclerosis Research Trial]] | ||
|- | |- | ||
| EARLY | | [[EARLY]] | ||
| [[Eptifibatide For Acute Coronary Syndromes—Rapid Versus Late Administration For Therapeutic Yield]] | | [[Eptifibatide For Acute Coronary Syndromes—Rapid Versus Late Administration For Therapeutic Yield]] | ||
|- | |- | ||
| EARLY | | [[EARLY]] | ||
| [[Endothelin Antagonist Trial In Mildly Symptomatic Pulmonary Arterial Hypertension Patient]] | | [[Endothelin Antagonist Trial In Mildly Symptomatic Pulmonary Arterial Hypertension Patient]] | ||
|- | |- | ||
| EARLY ACS | | [[EARLY ACS]] | ||
| [[Early Glycoprotein IIb/IIia Inhibition In Non–St-Segment Elevation Acute Coronary Syndromes]] | | [[Early Glycoprotein IIb/IIia Inhibition In Non–St-Segment Elevation Acute Coronary Syndromes]] | ||
|- | |- | ||
| EARS | | [[EARS]] | ||
| [[European Atherosclerosis Research Study]] | | [[European Atherosclerosis Research Study]] | ||
|- | |- | ||
| EARTH | | [[EARTH]] | ||
| [[Endothelin Receptor Antagonist Trial In Heart Failure]] | | [[Endothelin Receptor Antagonist Trial In Heart Failure]] | ||
|- | |- | ||
| EASE | | [[EASE]] | ||
| [[Ezetimibe Add-On To Statin Therapy For Effectiveness Trial]] | | [[Ezetimibe Add-On To Statin Therapy For Effectiveness Trial]] | ||
|- | |- | ||
| EAST | | [[EAST]] | ||
| [[Emory Angioplasty Vs Surgery Trial]] | | [[Emory Angioplasty Vs Surgery Trial]] | ||
|- | |- | ||
| EASTER | | [[EASTER]] | ||
| [[Estrogen And Stents To Eliminate Restenosis]] | | [[Estrogen And Stents To Eliminate Restenosis]] | ||
|- | |- | ||
| EASY | | [[EASY]] | ||
| [[Early Discharge After Transradial Stenting Of Coronary Arteries]] | | [[Early Discharge After Transradial Stenting Of Coronary Arteries]] | ||
|- | |- | ||
| EASYAS | | [[EASYAS]] | ||
| [[Eastbourne Syncope Assessment Study]] | | [[Eastbourne Syncope Assessment Study]] | ||
|- | |- | ||
| ECASS III | | [[ECASS III]] | ||
| [[European Cooperative Acute Stroke Study III]] | | [[European Cooperative Acute Stroke Study III]] | ||
|- | |- | ||
| ECCE | | [[ECCE]] | ||
| [[Effects Of Captopril On Cardiopulmonary Exercise Parameters (Ecce)]] | | [[Effects Of Captopril On Cardiopulmonary Exercise Parameters (Ecce)]] | ||
|- | |- | ||
| ECCO 2000 | | [[ECCO 2000]] | ||
| [[Effects Of Citicoline (Ceraxon) On Clinical Outcome - 2000 Mg ]] | | [[Effects Of Citicoline (Ceraxon) On Clinical Outcome - 2000 Mg ]] | ||
|- | |- | ||
| ECHO in PPH | | [[ECHO in PPH]] | ||
| [[Echocardiographic Predictors Of Adverse Outcomes In Primary Pulmonary Hypertension.]] | | [[Echocardiographic Predictors Of Adverse Outcomes In Primary Pulmonary Hypertension.]] | ||
|- | |- | ||
| ECLA GIK | | [[ECLA GIK]] | ||
| [[Estudios Cardiologicos Latinoamerica Glucose-Insulin-Potassium Pilot Trial]] | | [[Estudios Cardiologicos Latinoamerica Glucose-Insulin-Potassium Pilot Trial]] | ||
|- | |- | ||
| ECLIPSE | | [[ECLIPSE]] | ||
| [[Ensure's Vascular Closure Device Speeds Hemostasis Trial]] | | [[Ensure's Vascular Closure Device Speeds Hemostasis Trial]] | ||
|- | |- | ||
| ECRIS | | [[ECRIS]] | ||
| [[Endocoronary-Rhenium-Irradiation-Study]] | | [[Endocoronary-Rhenium-Irradiation-Study]] | ||
|- | |- | ||
| ECSG-1 | | [[ECSG-1]] | ||
| [[European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator]] | | [[European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator]] | ||
|- | |- | ||
| ECSG-6 | | [[ECSG-6]] | ||
| [[European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator II]] | | [[European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator II]] | ||
|- | |- | ||
| ECSS | | [[ECSS]] | ||
| [[European Coronary Surgery Study Group]] | | [[European Coronary Surgery Study Group]] | ||
|- | |- | ||
| ECST | | [[ECST]] | ||
| [[European Carotid Surgery Trial]] | | [[European Carotid Surgery Trial]] | ||
|- | |- | ||
| EDGECAP | | [[EDGECAP]] | ||
| [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Community-Acquired Pneumonia]] | | [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Community-Acquired Pneumonia]] | ||
|- | |- | ||
| EDGESST | | [[EDGESST]] | ||
| [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Skin And Soft Tissue Infections]] | | [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Skin And Soft Tissue Infections]] | ||
|- | |- | ||
| EDGE | | [[EDGE]] | ||
| [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities]] | | [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities]] | ||
|- | |- | ||
| EDGEUTI | | [[EDGEUTI]] | ||
| [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Urinary Tract Infection]] | | [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Urinary Tract Infection]] | ||
|- | |- | ||
| ED-IMPACT | | [[ED-IMPACT]] | ||
| [[Emergency Department Impedance Cardiography-Aided Assessment Changes Therapy Sponsor: Cardiodynamics International]] | | [[Emergency Department Impedance Cardiography-Aided Assessment Changes Therapy Sponsor: Cardiodynamics International]] | ||
|- | |- | ||
| EFICAT | | [[EFICAT]] | ||
| [[Ejection Fraction In Cardiac Transplant Patients]] | | [[Ejection Fraction In Cardiac Transplant Patients]] | ||
|- | |- | ||
| EGASIS | | [[EGASIS]] | ||
| [[Early Gaba-Ergic Activation Sin Troke]] | | [[Early Gaba-Ergic Activation Sin Troke]] | ||
|- | |- | ||
| ELATE | | [[ELATE]] | ||
| [[ Extended Low-Intensity Anticoagulation For Thrombo-Embolism Investigators]] | | [[Extended Low-Intensity Anticoagulation For Thrombo-Embolism Investigators]] | ||
|- | |- | ||
| ELECT | | [[ELECT]] | ||
| [[Evaluating Enoxaparin (Lovenox) Clotting Times]] | | [[Evaluating Enoxaparin (Lovenox) Clotting Times]] | ||
|- | |- | ||
| ELITE | | [[ELITE]] | ||
| [[Evaluation Of Losartan In The Elderly]] | | [[Evaluation Of Losartan In The Elderly]] | ||
|- | |- | ||
| [[ELITE-II]] | |||
| [[ | |||
| [[Losartan Heart Failure Survival Study]] | | [[Losartan Heart Failure Survival Study]] | ||
|- | |- | ||
| ELLDOPA | | [[ELLDOPA]] | ||
| [[Earlier Versus Later Levodopa In Parkinson Disease]] | | [[Earlier Versus Later Levodopa In Parkinson Disease]] | ||
|- | |- | ||
| ELUTES | | [[ELUTES]] | ||
| [[European Evaluation Of Paclitaxel Eluting Stent]] | | [[European Evaluation Of Paclitaxel Eluting Stent]] | ||
|- | |- | ||
| ELVD-CHF | | [[ELVD-CHF]] | ||
| [[Exercise In Left Ventricular Dysfunction And Chronic Heart Failure Trial]] | | [[Exercise In Left Ventricular Dysfunction And Chronic Heart Failure Trial]] | ||
|- | |- | ||
| EMERALD | | [[EMERALD]] | ||
| [[Enhanced Myocardial Efficacy And Removal By Aspiration Of Liberated Debris]] | | [[Enhanced Myocardial Efficacy And Removal By Aspiration Of Liberated Debris]] | ||
|- | |- | ||
| EMERALD | | [[EMERALD]] | ||
| [[European And Australian Multicenter Evaluative Research On Atrial Fibrillation—Dofetilide]] | | [[European And Australian Multicenter Evaluative Research On Atrial Fibrillation—Dofetilide]] | ||
|- | |- | ||
| EMERAS | | [[EMERAS]] | ||
| [[Estudio Multicentrico Estreptoquinasa Republicas De America Del Sur]] | | [[Estudio Multicentrico Estreptoquinasa Republicas De America Del Sur]] | ||
|- | |- | ||
| EMIAT | | [[EMIAT]] | ||
| [[European Myocardial Infarction Amiodarone Trial]] | | [[European Myocardial Infarction Amiodarone Trial]] | ||
|- | |- | ||
| EMIP | | [[EMIP]] | ||
| [[Prehospital Thrombolytic Therapy In Patients With Suspected Acute Myocardial Infarction]] | | [[Prehospital Thrombolytic Therapy In Patients With Suspected Acute Myocardial Infarction]] | ||
|- | |- | ||
| EMIP-FR | | [[EMIP-FR]] | ||
| [[European Myocardial Infarction Project—Free Radicals]] | | [[European Myocardial Infarction Project—Free Radicals]] | ||
|- | |- | ||
| EMIT | | [[EMIT]] | ||
| [[European Mivazerol Trial]] | | [[European Mivazerol Trial]] | ||
|- | |- | ||
| EMPIRIC | | [[EMPIRIC]] | ||
| [[Comparison Of Empiric To Physician-Tailored Programming Of Implantable Cardioverter Defibrillators Trial]] | | [[Comparison Of Empiric To Physician-Tailored Programming Of Implantable Cardioverter Defibrillators Trial]] | ||
|- | |- | ||
| ENABLE | | [[ENABLE]] | ||
| [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | | [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | ||
|- | |- | ||
| ENABLE | | [[ENABLE]] | ||
| [[Endothelin Antagonist Bosentan For Lowering Cardiac Events In Heart Failure]] | | [[Endothelin Antagonist Bosentan For Lowering Cardiac Events In Heart Failure]] | ||
|- | |- | ||
| ENCOR | | [[ENCOR]] | ||
| [[Enrasentan Cooperative Randomized Evaluation]] | | [[Enrasentan Cooperative Randomized Evaluation]] | ||
|- | |- | ||
| ENCORE | | [[ENCORE]] | ||
| [[Evaluation Of Nifedipine And Cerivastatin On The Recovery Of Endothelial Function Web Site]] | | [[Evaluation Of Nifedipine And Cerivastatin On The Recovery Of Endothelial Function Web Site]] | ||
|- | |- | ||
| ENCORE I | | [[ENCORE I]] | ||
| [[Evaluation Of Nifedipine And Cerivastatin On Recovery Of Coronary Endothelial Function]] | | [[Evaluation Of Nifedipine And Cerivastatin On Recovery Of Coronary Endothelial Function]] | ||
|- | |- | ||
| ENCORE II | | [[ENCORE II]] | ||
| [[Long-Term Effect Of Nifedipine On Vasomotion And Vessel Morphology In Patients With Coronary Artery Disease: An Intravascular Ultrasound-Assisted Evaluation]] | | [[Long-Term Effect Of Nifedipine On Vasomotion And Vessel Morphology In Patients With Coronary Artery Disease: An Intravascular Ultrasound-Assisted Evaluation]] | ||
|- | |- | ||
| ENDEAVOR II | | [[ENDEAVOR II]] | ||
| [[Randomized Comparison Of The Endeavor Abt-578 Drug Eluting Stent With A Bare Metal Stent For Coronary Revascularization]] | | [[Randomized Comparison Of The Endeavor Abt-578 Drug Eluting Stent With A Bare Metal Stent For Coronary Revascularization]] | ||
|- | |- | ||
| ENDEAVOR III | | [[ENDEAVOR III]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease]] | ||
|- | |- | ||
| ENDEAVOR IV | | [[ENDEAVOR IV]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease]] | ||
|- | |- | ||
| ENDEAVOR-1 | | [[ENDEAVOR-1]] | ||
| [[Multicenter Evaluation Of Abt-578 Elution From A Phosphorylcholine-Coated Stent]] | | [[Multicenter Evaluation Of Abt-578 Elution From A Phosphorylcholine-Coated Stent]] | ||
|- | |- | ||
| ENHANCE | | [[ENHANCE]] | ||
| [[Simvastatin With Or Without Ezetimibe In Familial Hypercholesterolemia]] | | [[Simvastatin With Or Without Ezetimibe In Familial Hypercholesterolemia]] | ||
|- | |- | ||
| [[ENRICHD]] | |||
| [[ | |||
| [[Enhancing Recovery In Coronary Heart Disease]] | | [[Enhancing Recovery In Coronary Heart Disease]] | ||
|- | |- | ||
| ENTIRE | | [[ENTIRE]] | ||
| [[Enoxaparin As Adjunctive Antithrombin Therapy For St-Elevation Myocardial Infarction]] | | [[Enoxaparin As Adjunctive Antithrombin Therapy For St-Elevation Myocardial Infarction]] | ||
|- | |- | ||
| ENTIRE | | [[ENTIRE]] | ||
| [[Enoxaparin And Tnk-Tpa With Or Without Gp IIb/IIia Inhibitor As Reperfusion Strategy In St Elevation Mi (TIMI-23) ]] | | [[Enoxaparin And Tnk-Tpa With Or Without Gp IIb/IIia Inhibitor As Reperfusion Strategy In St Elevation Mi (TIMI-23) ]] | ||
|- | |- | ||
| EPAMSA | | [[EPAMSA]] | ||
| [[Estudio Piloto Argentino De Muerte Subita Y Amioda Rone (Argentine Pilot Study Of Sudden Death And Amiodarone)]] | | [[Estudio Piloto Argentino De Muerte Subita Y Amioda Rone (Argentine Pilot Study Of Sudden Death And Amiodarone)]] | ||
|- | |- | ||
| EPAT | | [[EPAT]] | ||
| [[Estrogen In The Prevention Of Atherosclerosis Trial]] | | [[Estrogen In The Prevention Of Atherosclerosis Trial]] | ||
|- | |- | ||
| EPHESUS | | [[EPHESUS]] | ||
| [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | | [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | ||
|- | |- | ||
| EPHESUS | | [[EPHESUS]] | ||
| [[Eplerenone Neurohormonal Efficacy And Survival Study ]] | | [[Eplerenone Neurohormonal Efficacy And Survival Study ]] | ||
|- | |- | ||
| EPIC | | [[EPIC]] | ||
| [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | | [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | ||
|- | |- | ||
| EPIC | | [[EPIC]] | ||
| [[Evaluation Of C7E3 For Prevention Of Ischemic Complications]] | | [[Evaluation Of C7E3 For Prevention Of Ischemic Complications]] | ||
|- | |- | ||
| EPILOG | | [[EPILOG]] | ||
| [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | | [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | ||
|- | |- | ||
| EPILOG | | [[EPILOG]] | ||
| [[Evaluation In Ptca To Improve Long-Term Outcome With Abciximab Gp IIb/IIia Blockade ]] | | [[Evaluation In Ptca To Improve Long-Term Outcome With Abciximab Gp IIb/IIia Blockade ]] | ||
|- | |- | ||
| EPISTENT | | [[EPISTENT]] | ||
| [[Evaluation Of Platelet IIb/IIia Inhibitor For Stenting Trial]] | | [[Evaluation Of Platelet IIb/IIia Inhibitor For Stenting Trial]] | ||
|- | |- | ||
| EPOS | | [[EPOS]] | ||
| [[Elective Pci In Outpatient Study]] | | [[Elective Pci In Outpatient Study]] | ||
|- | |- | ||
| ERA | | [[ERA]] | ||
| [[Enoxaparin Restenosis (Era) Trial.]] | | [[Enoxaparin Restenosis (Era) Trial.]] | ||
|- | |- | ||
| ERA | | [[ERA]] | ||
| [[Early Rheumatoid Arthritis (Ra) Enoxaparin Restenosis After Angioplasty StudyEstrogen Replacement And Atherosclerosis Study]] | | [[Early Rheumatoid Arthritis (Ra) Enoxaparin Restenosis After Angioplasty StudyEstrogen Replacement And Atherosclerosis Study]] | ||
|- | |- | ||
| ERA (HRT) | | [[ERA (HRT)]] | ||
| [[Effect Of Estrogen Replacement On The Progression Of Coronary Artery Atherosclerosis]] | | [[Effect Of Estrogen Replacement On The Progression Of Coronary Artery Atherosclerosis]] | ||
|- | |- | ||
| ERACI | | [[ERACI]] | ||
| [[Estudio Randomizado Argentino De Angioplastia Vs. Cirugía (Argentine Randomized Trial Of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery In Multivessel Disease)]] | | [[Estudio Randomizado Argentino De Angioplastia Vs. Cirugía (Argentine Randomized Trial Of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery In Multivessel Disease)]] | ||
|- | |- | ||
| ERACI II | | [[ERACI II]] | ||
| [[Argentine Randomized Study: Coronary Angioplasty With Stenting Vs. Coronary Artery Bypass Surgery In Patients With Multiple-Vessel Disease (Eraci II): 30-Day And One Year Follow-Up Results]] | | [[Argentine Randomized Study: Coronary Angioplasty With Stenting Vs. Coronary Artery Bypass Surgery In Patients With Multiple-Vessel Disease (Eraci II): 30-Day And One Year Follow-Up Results]] | ||
|- | |- | ||
| ERASE | | [[ERASE]] | ||
| [[Emergency Room Assessment Of Sestamibi For Evaluation Of Chest Pain]] | | [[Emergency Room Assessment Of Sestamibi For Evaluation Of Chest Pain]] | ||
|- | |- | ||
| ERASE | | [[ERASE]] | ||
| [[Effects Of Rhdl On Atherosclerosis–Safety And Efficacy]] | | [[Effects Of Rhdl On Atherosclerosis–Safety And Efficacy]] | ||
|- | |- | ||
| ERASER | | [[ERASER]] | ||
| [[Evaluation Of Reopro And Stenting To Eliminate Restenosis]] | | [[Evaluation Of Reopro And Stenting To Eliminate Restenosis]] | ||
|- | |- | ||
| ERBAC | | [[ERBAC]] | ||
| [[Excimer Laser, Rotational Atherectomy, Balloon Angioplasty Complications Study]] | | [[Excimer Laser, Rotational Atherectomy, Balloon Angioplasty Complications Study]] | ||
|- | |- | ||
| ERGO | | [[ERGO]] | ||
| [[Etomoxir For The Recovery Of Glucose Oxidation]] | | [[Etomoxir For The Recovery Of Glucose Oxidation]] | ||
|- | |- | ||
| ERICA | | [[ERICA]] | ||
| [[Efficacy Of Ranolazine In Chronic Angina]] | | [[Efficacy Of Ranolazine In Chronic Angina]] | ||
|- | |- | ||
| ERNA | | [[ERNA]] | ||
| [[Early Return To Normal Activities At Two Weeks After Acute Myocardial Infarction: Preliminary Results Of A Randomized Study]] | | [[Early Return To Normal Activities At Two Weeks After Acute Myocardial Infarction: Preliminary Results Of A Randomized Study]] | ||
|- | |- | ||
| ER-TIMI | | [[ER-TIMI]] | ||
| [[Early Retavase - Thrombolysis In Myocardial Infarction]] | | [[Early Retavase - Thrombolysis In Myocardial Infarction]] | ||
|- | |- | ||
| ESCAMI | | [[ESCAMI]] | ||
| [[Evaluation Of The Safety And Cardioprotective Effects Of Eniporide In Acute Myocardial Infarction]] | | [[Evaluation Of The Safety And Cardioprotective Effects Of Eniporide In Acute Myocardial Infarction]] | ||
|- | |- | ||
| ESCAPE | | [[ESCAPE]] | ||
| [[Evaluation Study Of Congestive Heart Failure And Pulmonary Artery Catheterization Effectiveness]] | | [[Evaluation Study Of Congestive Heart Failure And Pulmonary Artery Catheterization Effectiveness]] | ||
|- | |- | ||
| ESCAPE | | [[ESCAPE]] | ||
| [[Evaluation Study Of Congestive Heart Failure And Pulmonary Artery Catheterization Effectiveness]] | | [[Evaluation Study Of Congestive Heart Failure And Pulmonary Artery Catheterization Effectiveness]] | ||
|- | |- | ||
| E-SIRIUS | | [[E-SIRIUS]] | ||
| [[European Sirolimus-Eluting Stent In Coronary Lesions]] | | [[European Sirolimus-Eluting Stent In Coronary Lesions]] | ||
|- | |- | ||
| ESPRIT | | [[ESPRIT]] | ||
| [[Enhanced Suppression Of The Platelet IIb/IIia Receptor With Integrilin TherapyEuropean Study Of The Prevention Of Reocclusion After Initial ThrombolysisEvaluation Of Subcutaneous Proleukin In A Randomized International Trial]] | | [[Enhanced Suppression Of The Platelet IIb/IIia Receptor With Integrilin TherapyEuropean Study Of The Prevention Of Reocclusion After Initial ThrombolysisEvaluation Of Subcutaneous Proleukin In A Randomized International Trial]] | ||
|- | |- | ||
| ESPRIT HRT | | [[ESPRIT HRT]] | ||
| [[Oestrogen In The Prevention Of Reinfarction Trial]] | | [[Oestrogen In The Prevention Of Reinfarction Trial]] | ||
|- | |- | ||
| ESPS2 | | [[ESPS2]] | ||
| [[European Stroke Prevention Study 2]] | | [[European Stroke Prevention Study 2]] | ||
|- | |- | ||
| ESPS-2 | | [[ESPS-2]] | ||
| [[European Stroke Prevention Study 2]] | | [[European Stroke Prevention Study 2]] | ||
|- | |- | ||
| ESSENCE | | [[ESSENCE]] | ||
| [[Efficacy And Safety Of Subcutaneous Enoxaparin In Unstable Angina And Non-Q-Wave Mi]] | | [[Efficacy And Safety Of Subcutaneous Enoxaparin In Unstable Angina And Non-Q-Wave Mi]] | ||
|- | |- | ||
| ESSENCE | | [[ESSENCE]] | ||
| [[Efficacy And Safety Of Subcutaneous Enoxaparin In Non–Q-Wave Coronary Events ]] | | [[Efficacy And Safety Of Subcutaneous Enoxaparin In Non–Q-Wave Coronary Events ]] | ||
|- | |- | ||
| ESSENTIAL | | [[ESSENTIAL]] | ||
| [[The Studies Of Oral Enoximone Therapy In Advanced Heart Failure]] | | [[The Studies Of Oral Enoximone Therapy In Advanced Heart Failure]] | ||
|- | |- | ||
| ESSENTIAL | | [[ESSENTIAL]] | ||
| [[The Studies Of Oral Enoximone Therapy In Advanced Heart Failure]] | | [[The Studies Of Oral Enoximone Therapy In Advanced Heart Failure]] | ||
|- | |- | ||
| ESTAT | | [[ESTAT]] | ||
| [[European Stroke Treatment With Ancrod Trial]] | | [[European Stroke Treatment With Ancrod Trial]] | ||
|- | |- | ||
| ESTEEM | | [[ESTEEM]] | ||
| [[Efficacy And Safety Of The Oral Direct Thrombin Inhibitor Ximelagatran In Patients After Acute Myocardial Infarction]] | | [[Efficacy And Safety Of The Oral Direct Thrombin Inhibitor Ximelagatran In Patients After Acute Myocardial Infarction]] | ||
|- | |- | ||
| ESVEM | | [[ESVEM]] | ||
| [[Electrophysiologic Study Versus Electrocardiographic Monitoring Trial]] | | [[Electrophysiologic Study Versus Electrocardiographic Monitoring Trial]] | ||
|- | |- | ||
| ETHECC | | [[ETHECC]] | ||
| [[Evaluation Of Thymitaq In Hepatocellular Carcinoma]] | | [[Evaluation Of Thymitaq In Hepatocellular Carcinoma]] | ||
|- | |- | ||
| ETICA | | [[ETICA]] | ||
| [[Exercise Training Intervention After Coronary Angioplasty: The Etica Trial]] | | [[Exercise Training Intervention After Coronary Angioplasty: The Etica Trial]] | ||
|- | |- | ||
| ETROP | | [[[ETROP]] | ||
| [[Early Treatment Of Retinopathy Of Prematurity]] | | [[Early Treatment Of Retinopathy Of Prematurity]] | ||
|- | |- | ||
| EURIDIS and ADONIS | | [[EURIDIS and ADONIS]] | ||
| [[Maintenance Of Sinus Rhythm With Dronedarone In Patients With Atrial Fibrillation Or Flutter]] | | [[Maintenance Of Sinus Rhythm With Dronedarone In Patients With Atrial Fibrillation Or Flutter]] | ||
|- | |- | ||
| EUROACTION | | [[EUROACTION]] | ||
| [[Nurse-Coordinated Multidisciplinary, Family-Based Cardiovascular Disease Prevention Programme]] | | [[Nurse-Coordinated Multidisciplinary, Family-Based Cardiovascular Disease Prevention Programme]] | ||
|- | |- | ||
| EUROCARE | | [[EUROCARE]] | ||
| [[Carvedilol For Prevention Of Restenosis After Directional Coronary Atherectomy]] | | [[Carvedilol For Prevention Of Restenosis After Directional Coronary Atherectomy]] | ||
|- | |- | ||
| EUROPA | | [[EUROPA]] | ||
| [[European Trial On Reduction Of Cardiac Events With Perindopril In Stable Coronary Artery Disease]] | | [[European Trial On Reduction Of Cardiac Events With Perindopril In Stable Coronary Artery Disease]] | ||
|- | |- | ||
| EURO-SPAH | | [[EURO-SPAH]] | ||
| [[European Sonotherapy Trial To Prevent Arterial Hyperplasia]] | | [[European Sonotherapy Trial To Prevent Arterial Hyperplasia]] | ||
|- | |- | ||
| Euro-SPAH | | [[Euro-SPAH]] | ||
| [[European-Sonotherapy Prevention Of Arterial Hyperplasia]] | | [[European-Sonotherapy Prevention Of Arterial Hyperplasia]] | ||
|- | |- | ||
| EUROSTAR | | [[EUROSTAR]] | ||
| [[European Cobalt Stent With Antiproliferative For Restenosis Trial]] | | [[European Cobalt Stent With Antiproliferative For Restenosis Trial]] | ||
|- | |- | ||
| EUTOPIA | | [[EUTOPIA]] | ||
| [[European Trial On Olmesartan And Pravastatin In Inflammation And Atherosclerosis]] | | [[European Trial On Olmesartan And Pravastatin In Inflammation And Atherosclerosis]] | ||
|- | |- | ||
| EVA | | [[EVA]] | ||
| [[Common Carotid Intima-Media Thickness Predicts Occurrence Of Carotid Atherosclerotic Plaques: Longitudinal Results From The Aging Vascular Study]] | | [[Common Carotid Intima-Media Thickness Predicts Occurrence Of Carotid Atherosclerotic Plaques: Longitudinal Results From The Aging Vascular Study]] | ||
|- | |- | ||
| EVA-AMI | | [[EVA-AMI]] | ||
| [[Eptifibatide Versus Abciximab In Primary Pci For Acute St Elevation Myocardial Infarction]] | | [[Eptifibatide Versus Abciximab In Primary Pci For Acute St Elevation Myocardial Infarction]] | ||
|- | |- | ||
| EVEREST | | [[EVEREST]] | ||
| [[Efficacy Of Vasopressin Antagonism In Heart Failure: Outcome Study With Tolvaptan]] | | [[Efficacy Of Vasopressin Antagonism In Heart Failure: Outcome Study With Tolvaptan]] | ||
|- | |- | ||
| EVEREST I | | [[EVEREST I]] | ||
| [[Endovascular Valve Edge-To-Edge Repair Study]] | | [[Endovascular Valve Edge-To-Edge Repair Study]] | ||
|- | |- | ||
| EVET | | [[EVET]] | ||
| [[Enoxaparin Versus Tinzaparin In Non-St-Segment Elevation Acute Coronary Syndromes]] | | [[Enoxaparin Versus Tinzaparin In Non-St-Segment Elevation Acute Coronary Syndromes]] | ||
|- | |- | ||
| EVIDENCE | | [[EVIDENCE]] | ||
| [[Evidence For Interferon Dose-Effect: European-North American Comparative Efficacy Study (Rebif V. Avonex In Relapsing-Remitting Multiple Sclerosis (Rrms))]] | | [[Evidence For Interferon Dose-Effect: European-North American Comparative Efficacy Study (Rebif V. Avonex In Relapsing-Remitting Multiple Sclerosis (Rrms))]] | ||
|- | |- | ||
| EVIDENT | | [[EVIDENT]] | ||
| [[Endo-Vascular Investigation Determining The Safety Of A New Tacrolimus Eluting Stent Graft]] | | [[Endo-Vascular Investigation Determining The Safety Of A New Tacrolimus Eluting Stent Graft]] | ||
|- | |- | ||
| EVIDENT | | [[EVIDENT]] | ||
| [[Endovascular Investigation Determining The Safety Of A New Tacrolimus-Eluting Stent Graft]] | | [[Endovascular Investigation Determining The Safety Of A New Tacrolimus-Eluting Stent Graft]] | ||
|- | |- | ||
| EXCITE | | [[EXCITE]] | ||
| [[Evaluation Of Oral Xemilofiban In Controlling Thrombotic Events]] | | [[Evaluation Of Oral Xemilofiban In Controlling Thrombotic Events]] | ||
|- | |- | ||
| EXCITE | | [[EXCITE]] | ||
| [[Evaluation Of Oral Xemilofiban In Controlling Thrombotic Events ]] | | [[Evaluation Of Oral Xemilofiban In Controlling Thrombotic Events ]] | ||
|- | |- | ||
| EXCITe | | [[EXCITe]] | ||
| [[Extremity Constraint-Induced Therapy]] | | [[Extremity Constraint-Induced Therapy]] | ||
|- | |- | ||
| EXCLAIM | | [[EXCLAIM]] | ||
| [[Extended Clinical Prophylaxis In Acutely Ill Medical Patients (Lovenox (Enoxaparin) Postmarketing (Phase Iv) Trial) ]] | | [[Extended Clinical Prophylaxis In Acutely Ill Medical Patients (Lovenox (Enoxaparin) Postmarketing (Phase Iv) Trial) ]] | ||
|- | |- | ||
| EXPEDITION | | [[EXPEDITION]] | ||
| [[Na+/H+ Exchange Inhibition To Prevent Coronary Events In Acute Cardiac Conditions]] | | [[Na+/H+ Exchange Inhibition To Prevent Coronary Events In Acute Cardiac Conditions]] | ||
|- | |- | ||
| EXPIRA | | [[EXPIRA]] | ||
| [[ Thrombectomy With Export Catheter In Infarct-Related Artery During Primary Percutaneous Coronary Intervention]] | | [[ Thrombectomy With Export Catheter In Infarct-Related Artery During Primary Percutaneous Coronary Intervention]] | ||
|- | |- | ||
| ExTRACT | | [[ExTRACT]] | ||
| [[Enoxaparin And Thrombolysis Reperfusion For Acute Myocardial Infarction Treatment]] | | [[Enoxaparin And Thrombolysis Reperfusion For Acute Myocardial Infarction Treatment]] | ||
|- | |- | ||
| F.I.R.E. | | [[F.I.R.E.]] | ||
| [[Efficacy Of Fx06 In The Prevention Of Myocardial Reperfusion Injury Trial]] | | [[Efficacy Of Fx06 In The Prevention Of Myocardial Reperfusion Injury Trial]] | ||
|- | |- | ||
| FAAT | | [[FAAT]] | ||
| [[Fatty Acid Antiarrhythmia Trial]] | | [[Fatty Acid Antiarrhythmia Trial]] | ||
|- | |- | ||
| FACET | | [[FACET]] | ||
| [[Flosequinan - Ace Inhibition Trial]] | | [[Flosequinan - Ace Inhibition Trial]] | ||
|- | |- | ||
| FACET | | [[FACET]] | ||
| [[Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial]] | | [[Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial]] | ||
|- | |- | ||
| FACIT | | [[FACIT]] | ||
| [[Folate After Coronary Intervention Trial]] | | [[Folate After Coronary Intervention Trial]] | ||
|- | |- | ||
| FACT | | [[FACT]] | ||
| [[Effect Of Nadroparin, A Low-Molecular-Weight Heparin, On Clinical And Angiographic Restenosis After Coronary Balloon Angioplasty]] | | [[Effect Of Nadroparin, A Low-Molecular-Weight Heparin, On Clinical And Angiographic Restenosis After Coronary Balloon Angioplasty]] | ||
|- | |- | ||
| FAME | | [[FAME]] | ||
| [[Fractional Flow Reserve Versus Angiography For Multivessel Evaluation]] | | [[Fractional Flow Reserve Versus Angiography For Multivessel Evaluation]] | ||
|- | |- | ||
| FAME | | [[FAME]] | ||
| [[Fluvastatin (Lescol) Assessment Of Morbi-Mortality In The Elderly]] | | [[Fluvastatin (Lescol) Assessment Of Morbi-Mortality In The Elderly]] | ||
|- | |- | ||
| FAMIS | | [[FAMIS]] | ||
| [[Fosinopril In Acute Myocardial Infarction Study]] | | [[Fosinopril In Acute Myocardial Infarction Study]] | ||
|- | |- | ||
| FANTASTIC | | [[FANTASTIC]] | ||
| [[Randomized Multicenter Comparison Of Conventional Anticoagulation Versus Antiplatelet Therapy In Unplanned And Elective Coronary Stenting]] | | [[Randomized Multicenter Comparison Of Conventional Anticoagulation Versus Antiplatelet Therapy In Unplanned And Elective Coronary Stenting]] | ||
|- | |- | ||
| FAST | | [[FAST]] | ||
| [[Femoral Artery Stenting Trial]] | | [[Femoral Artery Stenting Trial]] | ||
|- | |- | ||
| FASTER | | [[FASTER]] | ||
| [[Fibrinolytic And Aggrastat St Elevation Resolution First Abarelix Depot Study For Treating Endometriosis RapidlyFirst And Second Trimester Evaluation Of Risk]] | | [[Fibrinolytic And Aggrastat St Elevation Resolution First Abarelix Depot Study For Treating Endometriosis RapidlyFirst And Second Trimester Evaluation Of Risk]] | ||
|- | |- | ||
| FAST-MAG | | [[FAST-MAG]] | ||
| [[Field Administration Of Stroke Therapy - Magnesium]] | | [[Field Administration Of Stroke Therapy - Magnesium]] | ||
|- | |- | ||
| FATS | | [[FATS]] | ||
| [[Familial Atherosclerosis Treatment Study]] | | [[Familial Atherosclerosis Treatment Study]] | ||
|- | |- | ||
| FEMINA | | [[FEMINA]] | ||
| [[Addition Of Felodipine To Metoprolol Vs. Replacement Of Metoprolol By Felodipine In Patients With Angina Pectoris Despite Adequate Beta-Blockade]] | | [[Addition Of Felodipine To Metoprolol Vs. Replacement Of Metoprolol By Felodipine In Patients With Angina Pectoris Despite Adequate Beta-Blockade]] | ||
|- | |- | ||
| FERRIC-HF | | [[FERRIC-HF]] | ||
| [[Effect Of Intravenous Ferrous Sucrose On Exercise Capacity In Chronic Heart Failure]] | | [[Effect Of Intravenous Ferrous Sucrose On Exercise Capacity In Chronic Heart Failure]] | ||
|- | |- | ||
| FEST | | [[FEST]] | ||
| [[Fosinopril Efficacy/Safety Trial]] | | [[Fosinopril Efficacy/Safety Trial]] | ||
|- | |- | ||
| FIELD | | [[FIELD]] | ||
| [[Fenofibrate Intervention And Event Lowering In Diabetes]] | | [[Fenofibrate Intervention And Event Lowering In Diabetes]] | ||
|- | |- | ||
| FIELD | | [[FIELD]] | ||
| [[Fenofibrate (Tricor) Intervention And Event Lowering In Diabetes]] | | [[Fenofibrate (Tricor) Intervention And Event Lowering In Diabetes]] | ||
|- | |- | ||
| FINESSE | | [[FINESSE]] | ||
| [[Facilitated Intervention With Enhanced Reperfusion Speed To Stop Events]] | | [[Facilitated Intervention With Enhanced Reperfusion Speed To Stop Events]] | ||
|- | |- | ||
| FIRE | | [[FIRE]] | ||
| [[Filterwire Ex Randomized Evaluation]] | | [[Filterwire Ex Randomized Evaluation]] | ||
|- | |- | ||
| FIRST | | [[FIRST]] | ||
| [[Flolan International Randomized Survival Trial (Phase IIi (Develop Economic Data))]] | | [[Flolan International Randomized Survival Trial (Phase IIi (Develop Economic Data))]] | ||
|- | |- | ||
| FIRST | | [[FIRST]] | ||
| [[Flolan (Dobutamine) International Randomized Survival Trial First Trimester Integrated Risk Screening For Trisomy]] | | [[Flolan (Dobutamine) International Randomized Survival Trial First Trimester Integrated Risk Screening For Trisomy]] | ||
|- | |- | ||
| FLARE | | [[FLARE]] | ||
| [[Fluvastatin Angioplasty Restenosis]] | | [[Fluvastatin Angioplasty Restenosis]] | ||
|- | |- | ||
| FLARE | | [[FLARE]] | ||
| [[Fluvastatin (Lescol) Angiographic Restenosis]] | | [[Fluvastatin (Lescol) Angiographic Restenosis]] | ||
|- | |- | ||
| FLORIDA | | [[FLORIDA]] | ||
| [[Fluvastatin On Risk Diminishing After Acute Myocardial Infarction]] | | [[Fluvastatin On Risk Diminishing After Acute Myocardial Infarction]] | ||
|- | |- | ||
| FLUCAD | | [[FLUCAD]] | ||
| [[Influenza Vaccination In Secondary Prevention From Coronary Ischemic Events In Coronary Artery Disease]] | | [[Influenza Vaccination In Secondary Prevention From Coronary Ischemic Events In Coronary Artery Disease]] | ||
|- | |- | ||
| FOOD | | [[FOOD]] | ||
| [[Feed Or Ordinary Diet]] | | [[Feed Or Ordinary Diet]] | ||
|- | |- | ||
| FOSIT | | [[FOSIT]] | ||
| [[Fosamax International Trial]] | | [[Fosamax International Trial]] | ||
|- | |- | ||
| FRAXIS | | [[FRAXIS]] | ||
| [[Fraxiparin Versus Unfractionated Heparin In The Treatment Of Unstable Angina]] | | [[Fraxiparin Versus Unfractionated Heparin In The Treatment Of Unstable Angina]] | ||
|- | |- | ||
| FRAXIS / FRAX.I.S. | | [[FRAXIS / FRAX.I.S.]] | ||
| [[Fraxiparine In Ischemic Syndromes]] | | [[Fraxiparine In Ischemic Syndromes]] | ||
|- | |- | ||
| FRESCO | | [[FRESCO]] | ||
| [[Investigators In The Florence Randomized Elective Stenting In Acute Coronary Occlusions]] | | [[Investigators In The Florence Randomized Elective Stenting In Acute Coronary Occlusions]] | ||
|- | |- | ||
| FRIC | | [[FRIC]] | ||
| [[Fragmin In Unstable Coronary Artery Disease]] | | [[Fragmin In Unstable Coronary Artery Disease]] | ||
|- | |- | ||
| FRIC | | [[FRIC]] | ||
| [[Fragmin In Unstable Coronary Artery Disease]] | | [[Fragmin In Unstable Coronary Artery Disease]] | ||
|- | |- | ||
| FRISC | | [[FRISC]] | ||
| [[Fast Revascularization During Instability In Coronary Artery Disease]] | | [[Fast Revascularization During Instability In Coronary Artery Disease]] | ||
|- | |- | ||
| FRISC II | | [[FRISC II]] | ||
| [[Fragmin And Fast Revascularization During Instability In Coronary Artery Disease]] | | [[Fragmin And Fast Revascularization During Instability In Coronary Artery Disease]] | ||
|- | |- | ||
| FROST | | [[FROST]] | ||
| [[French Optimal Stenting Trial]] | | [[French Optimal Stenting Trial]] | ||
|- | |- | ||
| FROSTY | | [[FROSTY]] | ||
| [[Freezor Trial Of Supraventricular Tachycardia]] | | [[Freezor Trial Of Supraventricular Tachycardia]] | ||
|- | |- | ||
| FTT | | [[FTT]] | ||
| [[Fibrinolytic Therapy Trialists' Collaborative Group]] | | [[Fibrinolytic Therapy Trialists' Collaborative Group]] | ||
|- | |- | ||
| FUSION | | [[FUSION]] | ||
| [[Fractional Flow Reserve And Ultrasound Indices For Objective Narrowing Assessment]] | | [[Fractional Flow Reserve And Ultrasound Indices For Objective Narrowing Assessment]] | ||
|- | |- | ||
| FUSION I | | [[FUSION I]] | ||
| [[Follow-Up Serial Infusions Of Nesiritide Trial]] | | [[Follow-Up Serial Infusions Of Nesiritide Trial]] | ||
|- | |- | ||
| FUTURE I | | [[FUTURE I]] | ||
| [[First Use To Underscore Restenosis Reduction With Everolimus]] | | [[First Use To Underscore Restenosis Reduction With Everolimus]] | ||
|- | |- | ||
| FUTURE II | | [[FUTURE II]] | ||
| [[Multicenter Evaluation Of The Biosbsorbable Polymer-Based Everolimus-Eluting Stent]] | | [[Multicenter Evaluation Of The Biosbsorbable Polymer-Based Everolimus-Eluting Stent]] | ||
|- | |- | ||
| GABI | | [[GABI]] | ||
| [[German Angioplasty Vs. Bypass Surgery Investigation]] | | [[German Angioplasty Vs. Bypass Surgery Investigation]] | ||
|- | |- | ||
| GABI-2 | | [[GABI-2]] | ||
| [[German Angioplasty Bypass Investigation - 2]] | | [[German Angioplasty Bypass Investigation - 2]] | ||
|- | |- | ||
| GAMI | | [[GAMI]] | ||
| [[ Glucose Abnormalities In Patients With Myocardial Infarction: Prevalence, Diagnosis, And Prognostic Implications]] | | [[ Glucose Abnormalities In Patients With Myocardial Infarction: Prevalence, Diagnosis, And Prognostic Implications]] | ||
|- | |- | ||
| GAMMA II | | [[GAMMA II]] | ||
| [[Gamma II Localized Radiation Therapy To Inhibit Restenosis]] | | [[Gamma II Localized Radiation Therapy To Inhibit Restenosis]] | ||
|- | |- | ||
| GAMMA V | | [[GAMMA V]] | ||
| [[Gamma V Localized Radiation Therapy To Inhibit Restenosis]] | | [[Gamma V Localized Radiation Therapy To Inhibit Restenosis]] | ||
|- | |- | ||
| Gamma-One | | [[Gamma-One]] | ||
| [[Localized Intracoronary Gamma-Radiation Therapy To Inhibit The Recurrence Of Restenosis After Stenting]] | | [[Localized Intracoronary Gamma-Radiation Therapy To Inhibit The Recurrence Of Restenosis After Stenting]] | ||
|- | |- | ||
| GART study | | [[GART study]] | ||
| [[Genotypic Antiretroviral Resistance Testing]] | | [[Genotypic Antiretroviral Resistance Testing]] | ||
|- | |- | ||
| GEMICA | | [[GEMICA]] | ||
| [[Morbidity And Mortality Following Early Administration Of Amiodarone In Myocardial Infarction]] | | [[Morbidity And Mortality Following Early Administration Of Amiodarone In Myocardial Infarction]] | ||
|- | |- | ||
| GEMINI | | [[GEMINI]] | ||
| [[Glycemic Effects In Diabetes Mellitus: Carvedilol - Metoprolol Comparison In Hypertensives Trial]] | | [[Glycemic Effects In Diabetes Mellitus: Carvedilol - Metoprolol Comparison In Hypertensives Trial]] | ||
|- | |- | ||
| GEMS | | [[GEMS]] | ||
| [['Ginkgo Biloba 'Evaluation Memory Study]] | | [['Ginkgo Biloba 'Evaluation Memory Study]] | ||
|- | |- | ||
| GENESIS | | [[GENESIS]] | ||
| [[A Randomized, Multicenter Study Of The Pimecrolimus-Eluting And Pimecrolimus/Paclitaxel-Eluting Coronary Stent System In Patients With De Novo Lesions Of The Native Coronary Arteries]] | | [[A Randomized, Multicenter Study Of The Pimecrolimus-Eluting And Pimecrolimus/Paclitaxel-Eluting Coronary Stent System In Patients With De Novo Lesions Of The Native Coronary Arteries]] | ||
|- | |- |
Revision as of 17:41, 24 June 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
For other acronyms involved in clinical trials, click here
For detailed instructions on how to contribute to WikiDoc's Clinical Trials Wiki, click here